BIO&PHARMA IN BRUSSELS

EDITION 2010


Bio & Pharma
in Brussels

FOREWORD

The process of innovation in the "bio&pharma" fields is more and more linked to dynamic network of laboratories, specific services, star-ups, biotech and pharma companies.

Therefore the Brussel's Region on a limited space represents an ideal concentration of expertise as well for all new developments as for clinical research.

This brochure gives an overwiew of the academic area, companies, support organizations and incubators active in the "biotech" and "pharma" fields in the Brussels Capital-Region.

Are you looking for new partnership or have any project of implementation in the Brussels area, do not hesitate to contact either directly the companies, the universities, the institutions or :

BEA (The Brussels Enterprise Agency)

Pierre Lamy

Phone: **+32 2 422 00 24**

Fax: **+32 2 422 00 43**

E-mail: pla@bea.irisnet.be

CONTENTS

BIO&PHARMA
IN THE BRUSSELS-CAPITAL REGION

The Brussels-Capital Region with its central position in northern Europe has a population of one million (around 10% of the Belgian population). Even though the Region covers 161 km² (0,5% of the Belgian territory), it represents 15% of the global healthcare activity in Belgium comprising as well hospitals, private doctors, universities and industries.
The dynamism of the Brussels healthcare sector results from a close collaboration between universities, the industry and the support of the Regional Institutions. The presence in a small area of three main universities, a broad network of hospitals linked with these universities, is a favourable environment for the development of Life Sciences activities in the Brussels-Capital Region.

The Biotechnology & Pharmaceutical Market

The "Biotechnology" sector

Global revenues in the biotechnology sector for the public traded companies, in 2008 were 89.7 billion dollars. This underscores the emergence and importance of this sector throughout the world. In 2008, there were 4.717 companies in the biotechnology industry. The United States had 1.754 companies and employed 190.400 people compared to 1.836 companies with about 85.612 employed in Europe.
In 2006, Belgium was the 6th country in terms of biotech R&D expenditure with about 574 million PPP$, which represents 13% of total business expenditure. The Belgian biotech R&D firms employed 17.208 people with 5.608 employees dedicated to R&D.

The "Pharmaceutical" sector

In 2008, the global pharmaceutical market was 773 billion dollars with a growth of 4.8%. The European market was about 247.5 billion $ with 5.8% of growth while the US one was about 311.8 billion $ with 1.4% of growth. The Pharmaceutical Belgian market was estimated at 3.9 billion € in 2007 with an annual growth of 5.8%. In 2007, Belgian pharmaceutical R&D expenditure represented 6.2% of the European pharmaceutical R&D spending, and this expenditure was about 1 billion €. It should also be pointed out that employment in the pharmaceutical sector in 2007 was about 29.400 people, and 5.600 people worked in the R&D field. The employment registered an average annual growth of 3.7% from 1995.
We can also retain following figures from the Belgian pharma sector in 2007:

- Value of total production was about 5.22 billion €
- Exports went over 34.6 billion €
- Investments were about 631 million € despite some ups and downs in the economy

An adequate environment for Clinical Trials

- First member state to implement the European Clinical Trials directive 2001/20/EC: Belgian law of May 7, 2004
- The largest number of medicines in development in the world per capita
- The highest number of phase 1 trials in Europe per capita
- An average of 539 clinical trials per year were submitted at FAGG/AFMPS

The Brussels Bio&Pharma Sector

The Bio&Pharma in Brussels Cluster

"Bio&Pharma in Brussels" is the Brussels Region cluster supported by the Health Business Unit of BEA, the Brussels Enterprise Agency. It gathers the biotech and pharma players of the region and aims at increasing the visibility of the Brussels know-how, stimulating innovation, encouraging international partnerships and generating synergies between the players.
www.biopharmainbrussels.com

Companies in Brussels

The Brussels-Capital Region gathers a total of 106 "Bio&Pharma" companies, with 49 companies involved in R&D, production or services activities.



Research in the Brussels-Capital Region

In Brussels, the presence of 3 main universities, "ULB (Université Libre de Bruxelles)", "UCL (Université catholique de Louvain)" and the "VUB (Vrije Universiteit Brussel"), one "Haute Ecole", the "Meurice Institute" and "5 university hospitals", including almost 3.000 researchers in life sciences, has provided a favourable environment for the development of Bio&Pharma companies. The research is also supported by ISRIB (the Institute for the encouragement of Scientific Research

and Innovation of Brussels) with 4 programmes: "Brains back to Brussels", "Prospective Research for Brussels", "Impulse Programmes" and "Spin-off in Brussels".

Life Science Incubators

Incubation infrastructures have been created on the initiative of the Brussels-Capital Region in order to help start-ups and spin-offs.

BLSI (The Brussels Life Science Incubator) is located on the UCL site and provide specific accommodation for start-ups: offices, laboratories, logistic facilities,etc. Moreover, start-ups will benefit from the UCL support structure: SOPARTEC and its Vives investments fund, the Research Management Office of UCL and the Vésalius Scientific Park.

Eurobiotec Brussels is located in the Erasmus Industrial Zone in Brussels and is a Biotechnology Innovation & Incubation Centre involved in the emergence of new industrial activities in the white and red biotechnology. It offers to five young companies a combination of offices, fully-integrated serviced laboratories and customised technological and managerial supports. Apart its Bio-incubator activity, Eurobiotec is also a contract research/development organization.

EEBIC (The Erasmus European Business & Innovation Centre) created in 1992 offers more than 6.000 m² of premises, from offices to equipped laboratories, and a comprehensive administrative infrastructure which enables start-ups and spin-offs to grow up. The EEBIC team provides managerial advices, from the preparation of a business plan to intellectual property protection, in order to support pioneering projects development.

Solvay Research & Technology Centre has opened its largest research and development site to start-ups. Solvay Research & Technology Centre offers spaces for research, the necessary backing for their activity, particularly favourable conditions of accommodation for a period of two years, within the framework of an agreement where the start-up retains its full independence and the intellectual property rights on its research.

Financing possibilities

The Brussels Regional Investment Agency, Business Angels Connect, the Participation Fund, the Warranty Fund, Venture Capital providers and business oriented banks offer different possibilities of funding start-ups and fast growing companies. The Brussels Regional Authorities have created efficient financial mechanisms in order to support the scientific research and the technological development efforts of the companies in the Brussels area: subsidies or interest less loans can be obtained for R&D activities. Regional financial support can also be granted from the Foreign Trade Office for helping companies to export their products and services.

Business Development Support

Through its "Healthcare Business Unit", the Brussels Enterprise Agency (BEA) develops different kinds of services for the Brussels BioPharma players: technology and commercial partnership, strategic information, project validation, industry-university collaboration, participation to international events, communication tools development.

Think Europe, act from Brussels

Many people know Brussels as the political capital of Europe and the centre of many of the European institutions. Decisions affecting the life of 450 million people are taken here every day, and this is why Brussels has also become the home of many multinational headquarters. But other important factors have made Brussels one of the world's leading business centers. It is located at the heart of the wealthiest and most populated area of Europe. Sixty percent of the EU purchasing power lies in a 300 miles radius. Brussels International Airport is located 12 km from the city center and the new rapid train network (TGV) provides rapid rail services to Paris, London, Amsterdam and Frankfurt. Brussels is a city of 1 million inhabitants with an astonishing variety of cultures, styles and nationalities. Unlike other European capitals, it is large enough to be cosmopolitan and yet small enough to allow its inhabitants to enjoy all the advantages of a human size city. Geographically, economically and thanks to its outstanding quality of life, Brussels has convinced numerous overseas investors, from SME's to international headquarters to set up their company in this unique region.

Research Area Landscape

Companies involved in “Bio&Pharma” fields

INDEX

Incubators

Support Organizations

RESEARCH AREA LANDSCAPE

In the Research Area Landscape, Universities are key vehicles for technology transfer.

With 3 main universities, a broad network of hospital linked with these universities and research centers, the Brussels-Capital Region, in a restricted area, developed an important potential in research and clinical trials activities.

UCL (UNIVERSITÉ CATHOLIQUE DE LOUVAIN)

The Université catholique de Louvain (UCL) has a very high scientific potential in technologies related to the biotech, healthcare and pharma sectors.

Many research projects are performed both in Louvain-la-Neuve and on its biomedical campus in Brussels.

In Louvain-la-Neuve, the Institut of Life Sciences (ISV - www.uclouvain.be/en-isv.html) brings together 24 research groups from different faculties and departments. All these groups, involved in basic and applied projects, are using molecular and cell biology approaches to investigate the functioning of the living world, from the molecule to the whole organism. The ISV also aims to provide the researchers with a scientific environment favourable for productive collaboration and the emergence of young and promising research teams.

In Brussels, several teams of the Faculty of Medicine also belong to the de **Duve Institute** (www.deduveinstitute.be). This Institute pursues investigations in a great variety of fields. This diversity generates particularly fruitful exchanges that are made possible, beyond the differences among subjects, by the common concepts and methods characteristic of modern biology. The same tools are used and the same language is spoken, whether one looks at a virus, a microbe, a parasitic protist, an animal or a human being. The de Duve Institute also houses the Brussels branch of the Ludwig Institute for Cancer Research (www.bru.licr.org), active in the field of cancer immunology and cancer genetics.

The Brussels campus also hosts the Cliniques universitaires Saint Luc (www.saintluc.be) and the Brussels Life Science Incubator (www.blsincubator.com).

The first biopharmaceutical spin-off of UCL is Promethera Biosciences (www.promethera.com), that develops innovative treatments based on allogenic adult stem cell technology.

The Research Management Office of the UCL has edited a collection of booklets gathering the competences of its research units by themes. The main objective of these documents is to catalyse the development of scientific research, to promote synergies and to enrich the partnerships so as to develop the scientific assets at the industrial level and by the way, improve the health care quality.

Up to now, seven themes have been covered relative to the biotech, health care and pharma sectors:

- **Biotechnology and biomedical applications:** bioengineering, cell biology (animals and plants), immunology-microbiology, molecular biology, pharmacology-pharmacy-therapy and bioethics
- **Biomedical engineering:** bioinstrumentation, rehabilitation engineering, medical imaging and signal processing, biomaterials, sensors and biosensors and modelling of biological systems
- **Cancerology:** prevention and epidemiology, mechanisms of cancer, diagnostic-imaging, immunology-genetics, biomarkers, clinical studies, anti-cancer treatment, surgery, radiotherapy and psycho-oncology
- **ICT:** artificial intelligence and machine learning, bioinformatics, biomedical signal processing, human-computer interactions, systems and control
- **Materials:** biomaterials, catalytic materials, nanostructured materials, surfaces, coatings and thin films
- **Food sciences and nutrition:** nutrients and other components, biological targeting
- **Applied biology, agriculture and environment:** microbiology and plant health, ecosystems and plant production, biosynthesis-biotransformation-bioremediation

www.uclouvain.be/en-349.html

Illustrative research topics at UCL

Human healthcare applications

- New concepts for anti-angiogenic drugs – O. Feron, J. Quetin-Leclercq, O. Riant
- Keymarker: new biomarkers for medical imaging – F. Houssiau, P. Coulie, V. Grégoire
- Nanobiosensors & micro-arrays – S. Demoustier, JL. Gala, A. Jonas, B. Nysten
- In vitro cell culture systems – cell culture models for drug delivery – YJ. Schneider, S. Agathos, Y. Larondelle, V. Préat
- Odontological biomaterials – G. Leloup, J. Devaux
- Bone and tissue regeneration – C. Delloye, O. Cornu


© Jacky DELORME

- Cell therapy of liver diseases, Cellular immunity response towards viral pathogens cytokines, Yeast cells as therapeutic agents, Regenerative medicine of the liver - E. Sokal
- Ovarian cryobanking & transplantation – J. Donnez
- Culture of mammalian cells – C. Remacle
- Mono and polyclonal antibodies – P. Gianello
- Human tumor–specific antigens & vaccination – T. Boon
- Directed evolution of enzymes – P. Soumillion
- Metabolic basis of inherited disorders – E. Van Schaftingen, M. Veiga-da-Cunha
- DNA transposition / recombination mechanisms – B. Hallet
- Models for the study of neurodegenerative disorders – JN. Octave, E. Hermans, P. Kienlen-Campard
- Molecular genetics of vascular anomalies + biobank of vascular anomalies– M. Vikkula
- Transcription factors – R. Rezsohazy
- Mammalian antioxidant enzymes – B. Knoops, JP. Declercq, JF. Rees
- Protein structure analysis – JP. Declercq, M. Rider, L. Hue
- Multidrugs resistance – P. Tulkens
- Drug metabolism – P. Buc Calderon, N. Delzenne, P. Tulkens, P. Wallemacq
- Active metabolites from plants – J. Quetin-Leclercq, JL. Habib-Jiwan
- Pulmonary delivery of biotech drugs – R. Vanbever
- In vitro models for the evaluation of the cellular pharmacokinetics and pharmacodynamics of drugs; antibiotic resistance – P. Tulkens, F. Van Bambeke, MP. Mingeot
- Biodegradable carriers – J. Gillard
- Kidney diseases, dialysis, transplantation – O. Devuyst
- In vitro and in vivo evaluation systems for cardiovascular functions – JL. Balligand, C. Dessy, O. Feron, P. Sonveaux
- Obesity and metabolic syndrome – I. Leclercq, Y. Horsmans, N. Delzenne, JP. Thissen

Agricultural production applications

- Plant selection for phytoremediation - J-M. Kinet, S. Lutts
- In vitro production and cryopreservation of bovine of embryos - I. Donnay
- Valorization of plant microorganisms - H. Maraite, C. Bragard
- Plant cells as factories for pharmacological proteins – M. Boutry
- DNA fingerprinting and biodiversity measurement – F. Chaumont

Food biotechnology applications

- Brewery, food technology & food micro-biology - S. Collin, J. Mahillon, P. Hols
- Identification of bacterial human pathogens M. Delmée, T. Michiels

Industrial and environmental applications

- Nanotic (www.nanotic.net/home-english): swarm of intelligent sensors - more than 20 academics from the Faculties of Sciences, Applied Sciences, Medicine and Bio-engineering, Agronomy and Environment
- Interfaces studies – P. Bertrand, A. Delcorte
- Process modeling, monitoring, control and real-time optimization of biological processes – D. Dochain
- Environmental microbiology and bioprocess engineering – S. Agathos, S. Declerck, J. Mahillon
- Molecular design, preparation, production and shaping of heterogeneous catalysts – M. Devillers, E. Gaigneaux
- Materials with tunable acido-basic properties – E. Gaigneaux
- Nanostructured materials and nanobiomimetic surfaces – L. Piraux, C. Dupont, Y. Dufrêne
- Polymer materials with bioactive surfaces – J. Marchand-Brynaert

Technological platforms

- Transgenic mouse models
- Confocal microscopy and AFM
- Mass spectrometry and quantitative proteomics
- Cell and tissue imaging
- Protein crystallography
- Mycotheque
- Micro- and nanofabrication
- Bone bank
- Biochemical profiling in small animals
- Data analysis, biostatistics
- Electrical microsensors for DNA analysis
- Pediatric clinical investigation center
- Microarray platform
- Biosecurity L3 laboratories

For more information on research and development activities

The Université catholique de Louvain (UCL)
Research Management Office

Place de l'Université, 1
B - 1348 Louvain-la-Neuve (Belgium)

Phone: **+32 10 47 24 97**
Fax: **+32 10 47 48 30**

E-mail
info-adre@listes.uclouvain.be

Website
www.uclouvain.be/en-recherche.html

UCL

ULB (UNIVERSITÉ LIBRE DE BRUXELLES)

The "Hôpital Erasme" is the academic medical center of the "Université Libre de Bruxelles" (ULB) Brussels, Belgium.

There are also four university hospitals that are CHU Saint-Pierre, CHU Brugmann, Hôpital des Enfants Reine Fabiola (HUDERF) and Institut Jules Bordet. The "Université Libre de Bruxelles" has developed privileged relationships with HUDERF and Bordet.

Besides them, the "Université Libre de Bruxelles" also relies upon a vast hospital training network in Brussels and in the provinces of Brabant and Hainaut.

The Faculty of Medecine bases its teaching on research aimed at almost all the specialist fields.

This joint research gives rise to various fields of expertise and value creation, carried out in close collaboration with the University's other Faculties and with other Belgian and foreign research infrastructures, enabling this network to create a number of major growth fields in the Brussels region:

- Molecular biology
- Cancerology
- Immunology
- Pharmaceutical research
- Public health

Molecular Biology

The Faculty of Medicine at the ULB conducts both experimental and clinical research. The originality of its work stems most frequently from the combination of these two approaches: laboratory experiments explain clinical observations and the clinical application takes advantage of the basic discovery. This work notably makes it possible to establish the physiological roles of these receptors and their ligands and implications in various pathologies; the study of intercellular communication enables ideal targets to be identified for the development of novel therapeutic agents in such varied fields as neuropsychiatry, endocrinology, inflammatory illnesses and even the treatment of AIDS; research finds applications in the development of new vaccines, in the rational design of new medicines and the development of new therapeutic approaches such as immunotherapy and gene therapy.

Cancerology

The fight against cancer is the focus of major research efforts in the Brussels-Capital Region: The Institut Bordet (ULB) is the leading Belgian institution which is entirely devoted to screening, diagnosis and treatment of cancer whilst at the same time exercising a scientific, clinical and pedagogical activity for many cancer-related health problems.
This field of research has been the focus over recent years of numerous value creation activities (patents and creation of enterprises).

Immunology

Immunosuppression and organ transplants, immunodeficiency and new pathologies, cell marking and cancer therapies, etc are all application for this field of research, which has enabled the research units to be included in international networks and the development of new economic activities.

Pharmaceutical Research

The "Institut de Pharmacie" includes research units working in the field of medicine sciences and related sciences. Numerous research contracts are concluded with the pharmaceutical industry, notably to develop new medicines and to improve their conservation. The University's hospital infrastructures also make it possible to conduct clinical research for the private sector.

Public Health

The "Ecole de Santé Publique" develops activities in several fields related to public health: occupational medicine, industrial hygiene and the environment, community health, hospital and medico-social sciences, age-related problems and the health economy.
It undertakes numerous research projects in Belgium, at the European level and in developing countries, notably with regard to the following areas : epidemiological monitoring, toxicology, hospital planning, adolescent health, etc. Teams also focus on the influence of the working environment (noise, vibrations, temperature and lighting) on workers' health and well-being.
Others attempt to identify the health risks and acceptable exposure levels with regard to substances present in the environment.

Biotechnology laboratories at the ULB

Faculty of Medicine

Index of research units :
www.ulb.ac.be:rech/inventaire/facultes/medecine.html

Experimental research in physiology, histology, cytology and biochemistry

- Anatomy and embryology laboratory
- General histology laboratory
- Histopathology laboratory (HISTOPATHOL lab)
- Neurophysiology laboratory
- Physiology laboratory, Cellular Physiology Unit, Research Unit on ionic transport (CELL PHYSIO)
- Biomedical physics laboratory (LPBM)

Interdisciplinary Research Institute (IRIBHM)

- Biostatistics
- Study of the enzymes involved in the intracellular signals control (ampc, inositol phosphates)
- Interdisciplinary Research Institute in human and molecular biology (IRIBHM)
- Purinergic receptors
- Simulation
- Experimental dermatology unit
- Biotherapy and Oncology Research unit (RUBIO)
- Thyroid metabolism unit

Multidisciplinary laboratories

- Peptide metabolism research laboratory (LRMP)
- Metabolic flux regulations in vivo (FLUX METAB)

Research in Experimental medicine

- Molecular biology of diabetes (LABOMEDEX)
- Experimental surgery laboratory (L. Deloyers)
- Experimental medicine laboratory

- Experimental medicine laboratory (CHU VESALE)
- Parasitology laboratory
- Paediatric research laboratory
- Reproduction research laboratory
- Experimental intensive care laboratory

Medical biochemistry, microbiology, genetics and immunology
- Institute for Medical Immunology (IMI)
- Laboratory of Vaccinology and Mucosal Immunology (LOVMI)
- Immunology , Haematology, Transfusion Unit
- Molecular bacteriology laboratory (MBL)
- Biological and nutritional chemistry laboratory
- Molecular virology laboratory
- Protein Chemistry Unit (PCU)

Pharmacology
- Drug dynamics and therapeutics laboratory

Bordet Institute
- Radio oncology department
- Haematology laboratory (Institut Bordet)
- Experimental haematology laboratory
- Oncology and experimental surgery laboratory (L.O.C.E.)
- Gastroenterology oncology laboratory (LOGE)
- Laboratory J.-C. Heuson for mammary cancerology
- Anatomic pathology, cytology and cytogene tics department
- Anaesthesiology department
- Medical scanning department
- Surgery department
- Epidemiology and cancer prevention unit

Faculty of Sciences

Index of research units:
www.ulb.ac.be/rech/inventaire/facultes/sciences.html

Chemistry
- Theoretical biology and collective process
- Photochemistry
- Structure and function of the biological membranes (SFMB)

Molecular biology
- Molecular biology - bio-data processing (BIOINFO)
- Molecular biology - molecular embryology
- Molecular biology - genetic aspects of prokaryotes
- Molecular biology - genetics and cancer
- Molecular biology - cellular physiology laboratory - physiology of yeasts
- Molecular biology - molecular - parasitology
- Molecular biology - animal physiology and immunobiology
- Microbiology laboratory
- Biological chemistry department - molecular virology laboratory (HIV-BLV-HPV)
- Service for the conformation of biological macromolecules and bioinformatics
- Applied genetics department (SGA)
- Genetics and Evolution unit (UEG)
- RNA Metabolism (ARN)

Animal biology
- Human anthropology and genetics
- Biology of mammal behaviour (BIOMAM)
- Marine biology (BIOMAR)
- Functional morphology (Morfo)
- Experimental parasitology

Plant biology
- Plant biotechnology
- Progressive genetics and plant ecology (GEV)
- Physiology and molecular genetics of plants laboratory (LPGMP)
- Plant physiology laboratory

Agronomy interfaculty section (and bio-industries)
- Study and research group on the ovine race (GEROVIS)
- Laboratory for plant agrotechnology
- Biological oceanography and aquaculture laboratory
- Microbial physiology and ecology (UPEM)
- Animal cell biotechnology department (BIOCELAN)

For more information on research and development activities

The Université Libre de Bruxelles (ULB)

Avenue F.D. Roosevelt, 50 CP161
B - 1050 Brussels (Belgium)

Phone: **+32 2 650 45 71**
Fax: **+32 2 650 35 12**

E-mail
azèle.mathieu@ulb.ac.be.

Website
www.ulb.ac.be/rech/docs/ulbinter.html

Contact person
Azèle Mathieu

VUB (VRIJE UNIVERSITEIT BRUSSEL)

The "Vrije Universiteit Brussel" (VUB) is a dynamic and modern university with two parkland campuses in the Brussels Capital Region. The main campus in Etterbeek is home to seven faculties. The medical campus is located close to the university hospital, UZ Brussel (Jette). So is the healthcare campus of its association partner EhB (Erasmus University College Brussels). Together they form the "Universitaire Associatie Brussel" (UAB).

The Vrije Universiteit Brussel is the largest Dutch-speaking employer in the Brussels Region. Centrally situated in the capital of Europe, the university takes up its role as an ambassador for Flanders and Brussels, in a spirit of active pluralism and open-mindedness.

High quality education and research are central issues. More than 150 research teams are working on both our campuses. Our research teams are internationally recognised in many disciplines of fundamental and applied research. Thanks to this expertise and its strategic location, the Vrije Universiteit Brussel is your ideal partner for renowned research with an outlook on Europe and the world.
www.vub.ac.be

Research and Valorization at the "Vrije Universiteit Brussel"

The research activities of the "Vrije Universiteit Brussel" (VUB) are future-oriented and innovative. The university wants to play its role in the collaboration with industrial and economic actors in Belgium and abroad, through contract research for government and companies or any other type of collaboration with third parties. This includes the economic valorization of university research results through existing or new companies, the stimulation of entrepreneurship within its research community and the generation of new economic activity through the creation of spin-off companies based on university know-how and expertise. VUB-based research led to the creation of 24 spin-offs in a variety of domains of which 18 are active companies nowadays. Furthermore the university (co-) owns more than 100 patents and patent applications; part of them are licensed to spin-offs and other companies.

Building relations with industry is crucial: giving a tangible impact to our R&D by transferring results to industry, government and society, is a priority taken care of by the **Technology Transfer Interface or TTI** (www.vubtechtransfer.be).Contract research, protection of intellectual property, licence agreements, spin-off gui-dance, etc it all passes through the TTI, that knows how and where to find the right researchers to answer your questions.

Seed capital for start-ups of the Vrije Universiteit Brussel is provided by the **BI3-Fund** (Brussels Imagination, Innovation & Incubation Fund). The university co-manages two research parks: the research park Zellik in Flanders with incubation facilities (Innovation and Incubation Center Brussels - www.iicb.be) and Mercator at Neder-Over-Heembeek (Brussels). **ICAB** (Incubatiecentrum Arsenaal Brussel - www.icabrussel.be), a new incubator of the university for ICT and engineering spin-off companies, is fully operational since October 2009.

CROSSTALKS (http://crosstalks.vub.ac.be), the university and industry network of the Vrije Universiteit Brussel, is one of the tools bridging the gap between the academic and the industrial worlds. Since we live in a fast-moving and rapidly evolving society, long-term visions are fundamental, but scarce. The short-term agendas of decision-makers in the political, corporate, non-profit and academic worlds do not enable them. This is exactly where CROSSTALKS can make a difference. CROSSTALKS aims at creating an open and constructive exchange dynamic by hosting thematic encounters which go beyond the limitations of specific disciplines and which encourage active participation of key players from all levels of society.

Biotech and Pharma at the "Vrije Universiteit Brussel"

Molecular biology has known a spectacular evolution during the last decennia. It has found its way into health sciences and is undoubtedly influencing the way medical experts make their diagnosis or design medical treatments. Researchers at the Vrije Universiteit Brussel are at the cutting edge of science in many of the disciplines involved. To mention only a few: cancer related genes, stem cell research, proteins for signal transmission, molecular genetics of bacteria, peptides for tumour diagnosis and therapy, new fertilisation and reproduction techniques, transplantation of pancreatic cells for diabetes treatment, dendritic cells as therapeutic cancer vaccine, experimental in vitro toxicology, neuropharmacology, etc.

Many research units are member of **VIB**, the Flanders Interuniversity Institute for Biotechnology, a scientific research institute that groups 800 scientists and technicians from different Flemish universities (www.vib.be). Using advanced gene technology, VIB studies the functioning of the human body, plants and microorganisms.

Many of the laboratory activities and efforts at the Vrije Universiteit Brussel are oriented towards application in the university hospital. A lot of the high quality research performed at the Vrije Universiteit Brussel also results in collaboration projects with the biomedical and pharmaceutical industry as well as in the establishment of university spin-offs. ABLYNX is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins for a range of serious and life-threatening human diseases. The Department of Pharmaceutical and Biomedical Analysis of the Vrije Universiteit Brussel took the initiative for the "Virtual Institute for Chemometrics and Industrial Metrology" or VICIM (EU-project), a partnership of competence centres in six European countries. EGGCENTRIS is a spin-off of the Centre of Reproductive Medicine at the Vrije Universiteit Brussel, specialised in reproductive function testing.

In Brussels two spin-offs are active: "BruCells" that specialises in the development of new cancer vaccines and "Beta-Cell", a biotech company that arose from the Diabetes Research Center of the Vrije Universiteit Brussel and that develops novel cell therapy and other products related to diabetes.

The Laboratories of the "Vrije Universiteit Brussel"

Search engine for the research units and their activities at www.vub.ac.be/infovoor/onderzoekers/research/onderzoeksaanbod.html

Faculty of Medicine and Pharmacy
http://gf.vub.ac.be/english/index.html

- Medical biochemistry, Prof. Frans Gorus
- Centre for Reproductive Medicine, Prof. Karen Sermon
- Cell Biology and Histology, Prof. Alain Dupont
- Pathological Anatomy, Prof. Miriam Marichal
- Physiology , Prof. Kristiaan Thielemans
- Immunology and Microbiology, Prof. Benjamin Van Camp
- Pathologic Biochemistry and Physiology, Prof. Daniel Pipeleers
- Cell Differentiation, Prof. Luc Bouwens
- Pharmacology, Prof. Alain Dupont

The Center for Pharmaceutical Research (CePhaR) of the Vrije Universiteit Brussel consists of four units involved in various stages of pharmaceutical R&D, from early lead selection to the assessment of efficacy and safety of finished products:

- Toxicology , Pharmacognosy, Dermato, Cosmetology, Prof. Vera Rogiers
- Pharmaceutical Biotechnology and Molecular Biology, Prof. Bart Rombaut
- Analytical Chemistry and Pharmaceutical Technology, Prof. Yvan Vander Heyden
- Pharmaceutical Chemistry, Drug Analysis and Drug Information, Prof. Yvette Michotte

The university hospital UZ Brussel is situated near the medical campus and this facilitates close collaboration and interaction with the research groups of the faculty of Medicine and Pharmacy.

Faculty of Science and Bio-engineering Sciences
http://we.vub.ac.be/

- Analytical and Environmental Chemistry,Prof. Willy Baeyens
- Cell Genetics, Prof. Micheline Volders
- General Chemistry, Prof. Paul Geerlings
- Organic chemistry, Prof. Dirk Tourwé
- Physical and Colloidal Chemistry, Prof. Robert Finsy
- Protein Conformational Changes and Cellular Processes, Prof. Frederic Rousseau

The Institute of Molecular Biology and Biotechnology (IMOL) consists of 9 research groups that use diverse techniques to cover different disciplines and research topics. What unifies them, is the passion to study the structure and working of constituents of living organisms, cells, plants and bacteria. The knowledge they generate can be of fundamental importance in understanding the living world but can also be applied in the industry and in medicine and has resulted in intense collaborations with leading companies such as Solvay, GlaxoSmithKline, Innogenetics, etc.
http://imol.vub.ac.be

- Molecular and Biochemical Pharmacology, Prof. Georges Vauquelin
- Viral Genetics, Prof. Jean-Pierre Hernalsteens
- Microbiology and Genetics, Prof. Daniel Charlier
- Ultrastructure, Prof. Lode Wyns and Prof. Jan Steyaert
- Cellular and Molecular Immunology, Prof. Patrick De Baetselier and Prof. Serge Muyldermans
- Microbial Interactions, Prof. Pierre Cornelis
- Protein Chemistry, Prof. Sonia Beeckmans
- Industrial Microbiology and Food Bio-technology, Prof. Luc De Vuyst
- Plant Genetics, Prof. Geert Angenon

Faculty of Engineering
www.vub.ac.be/IR/

- Chemical engineering, Transport Modelling & (Bio) Analytical Seperation, Prof. Gert Desmet

For more information on research and development activities

Vrije Universiteit Brussel (VUB)
TTI, R&D Dept.

Pleinlaan 2
B - 1050 Brussels (Belgium)

Phone: **+32 2 629 22 07 or**
+32 2 629 21 08

E-mail
rd.interface@vub.ac.be

Website
www.vubtechtransfer.be

Contact person
Sonja Haesen
Head Technology Transfer Interface

CROSSTALKS
University and Industry Network of the Vrije Universiteit Brussel

Website
http://crosstalks.vub.ac.be

UZ Brussel
(Universitair Ziekenhuis Brussel)
Laarbeeklaan 101
B - 1090 Brussels (Belgium)

Contact person
Bart Stragier
Research Manager UZ Brussel

E-mail bart.stragier@vub.ac.be
Phone +32 2 476 36 30
Website www.uzbrussel.be

Vrije Universiteit Brussel

Technology Transfer Interface Brussels

HAUTE ECOLE LUCIA DE BROUCKÈRE

The "Meurice Institute", part of the Haute Ecole Lucia de Brouckère, delivers Master Industrial Engineers in Chemistry and Biochemistry grades. Moreover, since more than one century, the Meurice Institute works out R&D programs with the industrial world in the fields of applied microbiology, food processing and bio-processes, at Belgian and international level.
Capitalizing on more than 40 researchers experts in Life Sciences, the Institute actively participates to broadly applied research with future-oriented and innovative strategy including economic valorization through existing spin-off companies.

The Meurice Institute is located on the CERIA (Centre de Recherches des In-dustries Alimentaires et Chimiques) Campus in Brussels. Major research bioengineering units conducted in Meurice Institute are:

- Biotechnology Unit
- Brewery and Fermentation Unit
- Food Technology Unit
- Microbiology Unit
- Natural Substances Unit

The CIRIHA (Research and Information Center on Food Intolerances and Hygiene) provides expertise mainly in food intolerances analysis and in reduction of cardiovascular risks related to food practices.

The "BioTechnology Unit" (BTU) is an applied research centre is composed by the Microbial engineering and Chemical engineering departments.

BTU's thematics for innovative research achievements, strategic collaborations and technology transfers are:

- Isolation of natural strains of industrial interest (enzymes secretion, xenobiotics metabolisation)
- Microbial starters production for food- and bioepuration-technology
- Purification of recombinant proteins produced by genetically modified micro-organisms (E. coli, L. lactis, P. pastoris, S cerevisiae, etc)
- Development of fermentation processes with high biomass concentration
- Downstream processing development (UF, centrifugation, cell lysis, etc)
- Formulation by drying processes, immobilisation/coating of biological products and stability studies during storage
- Development of new processes in fermentation (batch, fed-batch, continuous process) for the food, environmental and pharmaceutical sectors with free or encapsulated living cells
- Production of natural antagonistic substances: organic acids, bacteriocins, biofungicides
- Computer-based design and liquid flows simulation of bioreactors
- Environmental technologies: specific biodegradating micro-organisms production, innovative bioprocesses for waste water and polluted air treatment

The unit owns several pilot equipments to test and to scale-up bioprocesses: fermentation units (from 2 to 200 l), large scale purification units, spraydryers (2 l/h to 20 l/h), fluidised bed dryers (capacity up to 5 kg), freeze-dryer, room for microbiological manipulations and encapsulation equipment.

The "Brewing Sciences and Fermentation Technology Unit" is active in research in fermentation. The brewing industry is certainly one of the oldest biotechnological industries, using yeast to transform sugar into alcohol.
Research activities include:

- Selection of industrial yeasts (brewing purpose, bioethanol production, etc)
- Yeast as eucaryotic model for cosmetic or pharmaceutical studies
- Microbial produced aromatic substances
- Natural antioxidants extraction from yeast
- Organoleptical stable fermented beverages
- Nutritional characterization of beer
- Development of new fermentation technologies
- Process improvement such as beer filtration

The unit provides also technical support to breweries and biochemical industries. It includes the common set of analyses usually performed on beer, on raw materials and biotech products, on the yeast maintenance and propagation as well as on-site consultancy and education and training for brewery's technicians.

The "Food Technology Unit" helps companies during the assessment of physical/chemical food and non-food products control. With the help of advanced analysis equipments, this unit is active in aromas and odours analysis, microbiological control, new products development, nutritional products, etc.

The Food Technology Unit encompasses 3 lab's .

1. **The laboratory for flavour analysis** is active in VOC's analysis by GC-MS sniffing for food or chemical products, etc.

2. **The laboratory for food processing and analysis** (member of IUPAC) provides skills in:
- Product research and development (formulation), new additives, ingredients, etc
- Product analysis
- Qualitative Analysis on micro-organisms by PCR-RT and ELISA*
- Allergens detection in foodstuff *

3. **The laboratory of Sensory Technologies Analysis** (LSTA) evaluates beverages, cosmetics, foods, fragrances, health care products, packaging, paints, etc using sensory analysis according to the AFNOR NF V 09-105 standards.

The lab is fully equipped with 17 testing boxes including mobile testing boxes and provides a complete and unique set of sensory tests (consumer tests, descriptive tests, discriminative tests, triangular tests, randomized tests).

In addition LSTA provides expertise and competencies in:

- Behavioural studies (medical and paramedical studies) for sensory preferences of elderly people
- Effects of zinc deficiency on sensory perceptions
- Effect of cancer treatment on food preferences

* In collaboration with the CIRIHA

The "Microbiology Unit" validates the efficiency of new products such as cleaning and desinfectant solutions, conservative factors developped by the food, the "soft drinks" and the brewery industries and the cosmetic field.
The microbiocide and/or microbiostatic product efficiency is evaluated through "challenge test" on several bacteria and fungi species which play a role in food and cosmetic products pathogenic contamination: Lactobacillus brevis, Pediococcus damnosus, Escherichia coli, Pseudomonas aeruginosa, Saccharomyces cerevisiae diastaticus, Candida albicans, Staphylococcus aureus, Aspergillus niger.
Tests are performed according to the European standards EN 1276, EN 1650 and C.O.L.I.P.A. standards.

The Natural Substances Unit analyzes protein pathways in order to solve medical deseases.
Researches are conducted in collaboration with RUG, ULB-Erasme (department of cyclotron), Institut Bordet (department of mammary oncology or department of melanoma cells) using ChemTech 90 solid phase peptide synthetizer, the Fmoc-chemistry method and the electrospray mass spectrometry for analysis and sequencing.
In the last years, the Unit evaluates models of synthesis pathways of the prion protein.

The Research and Information Center on Food Intolerances and Hygiene (CIRIHA) provides expertise mainly in food intolerances analysis and in reduction of cardiovascular risks related to food practices. The centre provides expertise for:

- Physicians: set-up of dedicated menus related to pathologies (obesity, allergy, etc)
- Food producers: development and nutritional valorisation of products (using the criteria's of the National Program Nutrition Health of Belgium), and scientific and legal advise in order to increase the products quality. In addition, the center helps companies to provide exact and simple nutritional informations to consumers (common and nutritional labelling, for example)
- Organisations: health policy and nutritional practices (food intake, set-up and control of menus, etc) for restaurants, rest houses, schools, etc with special training paths for people working in kitchen, etc.

For more information on research and development activities

InduTec
(Transfer Technology Center for the Brussels Industrial Engineering Institutes)
Avenue Nellie Melba, 73
B - 1070 Brussels (Belgium)

Phone: **+32 2 534 33 79**
Fax: **+32 2 534 33 95**

E-mail
doutrelepont@indutec.be

Website
www.indutec.be

Contact person
Céderic Doutrelepont



COMPANIES INVOLVED IN **"BIO&PHARMA" FIELDS**

With 52 "Bio&Pharma" companies involved in R&D, production or servicies activities, the Brussels-Capital Region represents an attractive and diversified panel of expertise.

Bio&Pharma in Brussels

ALFA LAVAL

AGROFOOD - INDUSTRIAL

ENGINEERING SOLUTIONS - TECHNOLOGY PROVIDER - CONSULTING ACTIVITIES (TECHNICAL ADVICES)

Avenue de Bâle, 5
B - 1040 Brussels (Belgium)

Phone: **+32 2 728 39 77**
Fax: **+32 2 728 38 03**

E-mail
frederic.mousty@alfalaval.com

Website
www.alfalaval.com

Contact person
Frédéric Mousty

Number of employees
50

Business model
Product provider

Activities in Brussels
Sales and enginering supply

Activities in other countries
All countries of the world

Corporate description

1883, that was the year when Gustaf de Laval founded the company that today is Alfa Laval. Its success was based on his brilliant invention of the continuous separator. Since then we have added heat transfer and fluid handling to our expertise in separation. We grow by helping our customers to grow. It's a fruitful partnership.

Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their processes. Time and time again. We help our customers to heat, cool, separate and transport products such as oil, water, chemicals, beverages, foodstuffs, starch and pharmaceuticals. Our worldwide organization works closely with customers in almost 100 countries to help them stay ahead.

Technology description

Centrifugal Separation

The need to separate different liquid phases and solids from each other is part of practically every industrial process. Alfa Laval has more than one hundred and twenty years of experience in meeting this requirement using either decanter or disc stack centrifuge technology, and our products perform this crucial function exceptionally well.

Filtration

Alfa Laval is the world leader in technologies for the mechanical separation of liquids.Alfa Laval is committed to develop our portfolio of filtration products in line with our goal to optimize the performance of your processes time and time again.

Fluid Handling

A reliable and continuous process flow is the key to consolidating your competitive edge.Through reliable fluid handling equipment that flow will be under your control.

Heat Transfer

Heating and cooling are essential parts of most industrial processes.
The demand is for these applications to be carried out with the least energy consumption. Heat exchangers provide an efficient technology for heating and cooling.

State of the technology

- Already on the market

AMGEN

HEALTHCARE

THERAPEUTICS (CELLS, ANTIBODIES) - DRUG FORMULATION - CONSULTING ACTIVITIES (REGULATORY AFFAIRS) - DATA MANAGEMENT FOR CLINICAL RESEARCH - MANUFACTURING SERVICES (CMO) - LOGISTICS FOR CLINICAL RESEARCH - MARKET ACCESS

Corporate description

Amgen is a leading human therapeutics company in the biotechnology industry and was one of the first companies to realize the new science's promise by bringing safe and effective medicines from laboratory, to manufacturing plant, to patient.
Headquartered in Thousand Oaks, California, Amgen is active in eight key therapeutic areas and has helped more than 13 million patients globally in cancer care, the treatment of anemia, rheumatoid arthritis, and other auto-immune diseases.
Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology.
Amgen now has over 25 years of experience in biotechnology medicines and is currently conducting extensive research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology with 50 products in the development pipeline. Amgen has been represented in Europe since 1989 and offers products to patients throughout the continent. Through the ongoing introduction of new products in Europe, the company expanded its direct patient reach and geographic footprint.

Amgen in Belgium

Amgen Belgium was established in 1990. Its activities now encompass clinical development, medical affairs, marketing & sales, corporate & regulatory affairs and general administration activities. It also hosts some regional headquarters activities. It employs today over 85 staff members. Amgen Belgium is particularly highly profiled for the clinical development of its drugs as can be evidenced by the high contribution to Belgian patient enrollment in Amgen studies: about 250 to 350 patients each year, representing 3,5% of all Amgen patient enrollments, are treated in Belgium. Proportionally this is significantly more than in surrounding countries. As a result, authors of peer-reviewed publications of Amgen studies are often Belgian investigators. These activities in clinical development also represent significant investments in Belgium, which are to the benefit of Belgian patients and hospitals and which also contribute favorably to local employment and medical expertise.

Technology description

Over the past quarter century, Amgen has pioneered the methods by which human proteins that play a role in disease processes are identified, isolated, produced in quantity and used as therapeutics. With expertise in proteins, small molecules, antibodies, peptibodies, and nucleicacids, Amgen's scientists can pursue the study of disease, choose the best target for a disease and then use the modality most likely to have an effect on that target. This approach positions Amgen as one of the only companies with capabilities across a range of modalities. The company has systematically invested more than 20 percent of product sales in research and development each year since 1994, and totalized approximately $3.2 billion in 2006. Amgen is committed to advancing the frontiers of science through the treatment of society's most grievously ill patients. More than half of our products in our current portfolio are first-in-class products; moreover, the majority of the molecules in our mid-stage pipeline work via a mechanism or hit a target that no other approved drug addresses.

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- Patents granted

Products description

Amgen is a global leader in biotechnology manufacturing, producing more than a third of the world's output of non-vaccine and non-insulin protein therapeutics. From process development to clinical manufacturing and full-scale therapeutic protein production, Amgen has built one of the largest and most reliable operations in the industry. The company operates state-of-the-art process development and/or product manufacturing facilities in California, Colorado, Rhode Island, Washington and Puerto Rico.
Amgen's manufacturing capabilities are further broadened by strategic relationships with a range of contract manufacturers in the United States, Europe, Canada and Japan.

Avenue Ariane, 5
B - 1200 Brussels (Belgium)

Phone: **+32 2 775 27 11**
Fax: **+32 2 264 26 00**

E-mail
annie.hubert@amgen.be

Website
www.amgen.be

Contact person
Annie Hubert

Date of establishment
1980 in California
1990 in Belgium

Number of employees
130

Number of employees in R&D activities
85

Business model
Product provider

Activities in Brussels
Headquarter
Research & Development
Distribution/Sales

Activities in other countries
Multinational companies established in most countries around the globe

ARTELIS

HEALTHCARE

THERAPEUTICS (HUMAN & VETERINARY VACCINES, PROTEINS, CELL THERAPY, ANTIBODIES, SMALL MOLECULES, GENERICS/BIOSIMILARS) - CELL CULTURE EXPERTISE - DEVICE FOR THE BIOPHARMA SECTOR - TECHNOLOGY PROVIDER

Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)

Phone: +32 2 264 18 80
Fax: +32 2 264 26 00

E-mail
info@artelis.be

Website
www.artelis.be

Contact persons
Jose Castillo
Hugues Bultot

Date of establishment
2005

Number of employees
31

Number of employees in R&D activities
18

Business model
Product & Service provider

Turnover
1.500k €

Activities in Brussels
Headquarter
Manufacturing
Product design and development

Corporate description

Artelis SA is an international technology company founded in 2005. The company is concerned with process intensification needs in the biotech industry and provides innovative upstream technologies for cell culture. Artelis' mission is to design, develop and manufacture the next generation means of production for vaccines and protein therapeutics as well as for cell therapy manufacturing.

Artelis is a fast-growing company whose management and development teams are made up of people with a wide experience into the industrial biotechnology. Thanks to its innovations strongly supported by successful collaborations, Artelis has rapidly become the privileged partner of world-leading pharmaceutical groups.

Technology description

Artelis has designed and developed iCELLis™: a scalable and single-use high-cell-density bioreactor that enables process intensification. iCELLis™ is a novel single-use bioreactor that achieves and maintains high density animal cell cultures (adherent or suspension) in a fixed-bed design operating in perfusion mode. Achieving high-cell densities enables compact iCELLis™ bioreactor to equal the output of much larger stirred tank units. 1L of iCELLis™ fixed-bed is equivalent to 20-100L of stirred tank volume depending on cell line and process. By reducing bioreactor scales, simplifying operations and consequently, dramatically decreasing capital and investment costs, iCELLis™ represents the next generation of disposable bioreactor.

State of the technology

- Already on the market
- Available for demonstration
- Development phase

Intellectual Property Rights (IPR)

- Licence agreements reached
- Partnership/Other contractual agreement
- Patent applied - not granted

Services description

Process development services in the field of cell culture and virus production.

Innovative aspects

- **Compact** – manufacturing scales are dramatically reduced, enabling portability and rapid deployment of the system

- **Scalable** – a process developed in a small-scale process development iCELLis™ can quickly be scaled to large-scale production iCELLis™
- **Controllable** – production scale iCELLis™ units are equipped with disposable probes and process controls
- **Disposable** – iCELLis™ bioreactors are completely disposable
- **Easy-to-use** - iCELLis™ units are supplied ready for quick installation and operation within simplified facilities

Research & Development

iCELLis™ 1000

Artelis has launched iCELLis™ 1000 bioreactor, a scalable and easy-to-use disposable bioreactor that provides 1,000 m² of cell-friendly growth support for virus and protein production.

iCELLis™ nano

Artelis is finalizing the development of iCELLis™ nano – the perfect plug & play tool for both process development and small scale protein/virus production. A series of beta tests have already started in collaboration with two worldwide-known companies: Merck Serono and Pfizer.

iCELLis™ for cell therapy

Regenerative medicines are expected to grow rapidly over the next decade and Artelis is taking part in this new challenging adventure! Artelis is collaborating with Cardio3 BioSciences to adapt its iCELLis ™ technology platform to the specific manufacturing process of cell therapies.

Type of partnership sought

- Further research/development support
- License agreements
- Manufacturing/Subcontracting agreement

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University

ASTRAZENECA

MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES

HEALTHCARE

Corporate description

We discover new medicines that are designed to improve the health and quality of life of patients around the world–medicines which are innovative, effective and which offer added benefits. We also focus on getting the best from every medicine we make by exploring all the ways it can be used or improved.

At AstraZeneca, innovation is about more than just research. We aim to stimulate continued creativity throughout our organization by maintaining a culture in which our people feel valued, energized and rewarded for their ideas and contribution to our success ideas which can make a difference in all aspects of our business. And we support and encourage our people in discovering their own potential, through excellent learning and development opportunities that are available to them throughout their careers.

With a global business comes a global responsibility for consistently high standards of behavior worldwide. We aim to effectively manage that responsibility and help to find new ways of bringing benefit to society to ensure that AstraZeneca continues to be welcomed as a valued member of the global community.

We are committed to continued achievement in all of these areas to ensure a healthy future for our business so that we can continue to help improve the lives of, and add value for, all those who benefit from it.

Rue E. Van Ophem, 110
B - 1180 Brussels (Belgium)

Phone: **+32 2 370 48 11**
Fax: **+32 2 332 29 69**

E-mail
info.be@astrazeneca.com

Website
www.astrazeneca.be

Date of establishment
1999

Number of employees
177

Activities in Brussels
Subsidiary company
Distribution/Sales
Phase II to phase IV coordination

Activities in other countries
Pharmaceutical industry (all around the world)

AstraZeneca

BETA-CELL

HEALTHCARE

THERAPEUTICS (CELLS) - CELL CULTURE EXPERTISE - DIAGNOSTIC TOOLS - DIABETES

Laarbeeklaan, 103
B - 1090 Brussels (Belgium)

Phone: **+32 2 477 43 49**
Fax: **+32 2 477 43 50**

E-mail
info@beta-cell.com

Website
www.beta-cell.com

Contact person
Sven Andréasson

Date of establishment
1998

Number of employees
8

Number of employees in R&D activities
7

Business model
Product & Service provider

Activities in Brussels
R&D: research
R&D: pre-clinical development
R&D: clinical development

Corporate description

BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes.
The company is a spin-off from the Brussels Free University - Diabetes Research Center (VUB-DRC), established in 1998. The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients. DRC is an internationally recognized center of excellence in the field of diabetes.
BETA-CELL's technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.
Recent developments have opened a second line in the field of beta cell regeneration, with BetaREG as a lead, and a third one in the field of drug screening and discovery, defined as BetaSCREEN.

Technology description

BETA-CELL occupies a unique position in the development of beta cell grafts with wide application using patented, validated and stringently tested products. Key features of the commercial BetaGRAFT are its ability to survive, function and grow in a selected microenvironment that includes a biocompatible barrier that protects the grafted cells from rejection and the host from possible side effects. In the meantime, BetaCELL co-develops BetaSCREEN (a drug screening and discovery platform) and BetaREG (beta cell regeneration).

State of the technology

- Development phase

Intellectual Property Rights (IPR)

- License agreements reached
- Partnership /Other contractual agreement
- Patents applied - not granted
- Patents granted



Innovative aspects

Beta-Cell is a spin-out from the Diabetes Research Center affiliated with the Free University of Brussels. DRC houses about 100 scientists, students and technicians devoted to the study of all the biological and medical aspects of diabetes and is also a major coordination center for human islet transplantation in Europe.

Research & Development

3 projects in R&D and pre-clinical stages.

- BetaGRAFT: cell therapy products in pre-clinical development.
- BetaSCREEN: screening technology ready for demonstration on lab-scale.
- BetaREG: R&D phase.

Type of partnership sought

- Financial resources
- Further research/development support
- License agreements

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University

BIO-LINE

HEALTHCARE

ALLERGY - DIABETES - INFECTIOUS DISEASES - STEROIDS

Corporate description

Bio-line sa established in January 1990 is specialized in the research, development and production of high quality kits for in vitro diagnostic specially designed for clinical analysis.

Bio-line sa produce immunoassays based on both RIA and EIA techniques for several products line: Fertility and Reproduction, Diabetes, Bone Metabolism, Cancer markers, Growth factors, Endocrinology, Thyroid function and Allergy.

Bio-line sa is already distributing its products in many countries in and outside Europe: Greece, Italy, Austria, Turkey, Korea, Czech Republic, India, Portugal, Suisse, etc.

Since 7th February 2005, Bio-Line s.a comply with the requirements of the European Directive 98/79/EC on in vitro diagnostic medical devices. Our products carry the CE mark as a sign of compliance with the essential requirements of the Directive.

Market

Distributors or final customers.

Technology description

Ria & Elisa.

State of the technology

- Already on the market

Research & Development

1 project in pre-production stage (horses allergies).

Type of partnership sought

- Distribution agreement
- Manufacturing/Subcontracting agreement

Type of partner sought

- Small to medium sized company

Rue André Fauchille, 17
B - 1150 Brussels (Belgium)

Phone: **+32 2 736 62 18**
Fax: **+32 2 743 16 15**

E-mail
bioline.ch@belgacom.net

Website
www.bio-line.eu

Contact persons
Daniel Declercq
Christian Plasschaert

Date of establishment
1990

Number of employees
2

Number of employees in R&D activities
1

Business model
Product provider

Activities in Brussels
Headquarter
R&D: research
Manufacturing
Marketing
Distribution

BIOREMEDIATION EUROPE

ENVIRONMENT - INDUSTRIAL

POLLUTION TREATMENT - MANUFACTURING SERVICES (CMO) - ORGANIC & NATURAL PRODUCTS FOR CLEANING AND DEGREASING

Rue Konkel, 105/107
B - 1150 Brussels (Belgium)

Phone: **+32 2 772 40 70**
Fax: **+32 2 772 30 65**

E-mail
bioremediation@skynet.be

Website
www.bioremediationeurope.com

Contact person
Jean-Luc Pleunes

Date of establishment
2001

Number of employees
2

Number of employees in R&D activities
1

Business model
Product provider

Activities in Brussels
Headquarter
R&D: research
Manufacturing
Marketing
Distribution

Activities in other countries
All European countries

BIOREMEDIATION EUROPE

Corporate description

Bioremediation

A recent technique, bioremediation uses the biological potential to induce and stimulate the natural degradation processes.
Either by potentiating the natural capacity of soil and water to purify themselves, or by using products from biology to prevent and solve pollution problems.

Bioremediation Europe sa: the Alternatives

The company is the realization of the project that its founding fathers have developed since 1996, convinced of the relevance and the exceptional potential of this approach.
Their aim: to seek and provide alternatives for the prevention and solution of environmental problems.

Industry and consumers in general have long hesitated to test these new products, despite a trend reflected in the search or solutions to replace chemicals by organic products.

Today, two phenomena modify this behavior: on the one hand, the awareness of having to save the planet and its natural resources, and, secondly, the establishment of the European REACH Law, which aims to better protect the user and his environment.

At the start of a new revolutionary concept of cleaning and bioactivating solutions, achieved by "simple" fermentation of an extract of Icelandic seaweed, the company markets new products and processes:

- on the one hand, at the service of sectors like metallurgical industry, catering, wastewater treatment facilities, public transport, or in terms of depolluting harbor and port water, and soils
- secondly, and most recently, for the consumer in two areas: household cleaning and vehicle cleaning

Genuinely Organic

The action of our 100% natural products rests on a combination of agents obtained by fermentation of an Icelandic seaweed. They also benefit from the synergy of their unique properties of surfactant, emulsifier and chelator. Some of them, moreover, are excellent bioactivators, which contributes to the effectiveness of wastewater treatment.

All our products have been formulated to serve two imperatives: effectiveness first, and second, protecting the user and the environment in a sustainable development perspective.

And some claim little or no water, which protects the reserves of this essential element to the survival of our planet!

Our Values

- Respect and improve the environment
- Create and market effective, useful products with a positive environmental impact
- An ongoing commitment to the company and its stakeholders

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- Exclusive rights

Type of partnership sought

- Distribution agreement

Type of partner sought

- Small to medium sized company

BOEHRINGER INGELHEIM

HEALTHCARE

CARDIOVASCULAR DISEASES - CNS - DIABETES - ONCOLOGY - RESPIRATORY DISEASES - HIV

Corporate description

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- Exclusive rights
- Partnership/Other contractual agreement

Research & Development

Molecules in development.

Type of partnership sought

- Universitary hospitals

Type of partner sought

- University

Avenue Ariane, 16
Vesalius Science Park
B - 1200 Brussels (Belgium)

Phone: **+32 2 773 33 11**
Fax: **+32 2 773 33 00**

E-mail
external@bru.boehringer-ingelheim.com

Website
www. boehringer-ingelheim.be

Contact person
Stefan Junqué

Date of establishment
1961

Number of employees
120

Number of employees in R&D activities
20

Business model
Product provider

Turnover
11,6 Billion € (2008) - Corporate

Activities in Brussels
R&D: clinical development
Marketing
Distribution & Sales

Activities in other countries
Headquarter
R&D: research
R&D: pre-clinical development
R&D: drug discovery
R&D: clinical development
Manufacturing
Marketing
Distribution
Luxemburg: Pharmaceutical products

Boehringer Ingelheim

BRABANT BIOTECH

HEALTHCARE

THERAPEUTICS (PROTEINS) - DRUG FORMULATION - DRUG DELIVERY - CELL CULTURE EXPERTISE - DRUG DISCOVERY/ SCREENING - CONSULTING ACTIVITIES - LEGAL SERVICES TO BIOTECH - DIABETES

Rue Forestière, 1 b7
B - 1050 Brussels (Belgium)

Phone: **+32 2 644 37 23**
Fax: **+32 2 644 14 49**

E-mail
sydney.schreiber@brabant.biotech.com

Website
www.brabantbiotech.com

Contact person
Sydney Schreiber

Date of establishment
2005

Number of employees
1

Number of employees in R&D activities
1

Business model
Product provider

Activities in Brussels
Headquarter

Activities in other countries
R&D: research
R&D: pre-clinical development
France, USA

Corporate description

Brabant Biotech's mission is to incorporate new strategies for improved oral and transdermal delivery of peptide based drugs, by utilizing recombinant protein methods and outsourced laboratory, clinical and manufacturing activities.



State of the technology

- Available for demonstration
- Development phase

Intellectual Property Rights (IPR)

- Exclusive rights
- Patents applied - not granted

Research & Development

One project in pre-clinical stage.

Type of partnership sought

- Financial resources
- Further research/development support
- Joint venture agreement
- License agreements

Type of partner sought

- Small to medium sized company
- Large company
- Research institute

Brabant Biotech

BRUCELLS

HEALTHCARE

THERAPEUTICS (CELLS, VACCINES) - CELL CULTURE EXPERTISE - ONCOLOGY

Corporate description

BruCells SA (the Company) was incorporated as a limited liability company on April 25, 2001 in order to develop the commercial applications of patent applications and knowhow from Université Libre de Bruxelles (ULB) and Vrije Universiteit Brussel (VUB) in the fields of cancer immunotherapy involving dendritic cells (DC). The collaboration was later extended to Université catholique de Louvain (UCL), the Ludwig Institute of Cancer Research (LICR), Vrije Universiteit Amsterdam, Würzburg University and Jikei University.
BruCells SA has developed a unique concept of cancer drug with wide therapeutic applications. The concept belongs to the new class of immunotherapies (cancer vaccines), which can be combined with existing and new reference treatments. The safety profile and the medical plausibility based on investigational clinical trials are excellent. The equity captal of the Company upon incorporation in 2001 was 750 K€. The capital has been increased in 2003, 2006 and 2008 to reach the current level of 4.3 M€. During its development since 2001, the Company has benefited from research and development grants from the Region of Brussels and has participated to 2 projects funded by the European Commission, totaling 4.7 M€. A total of 9 M€ has therefore been invested to reach the current stage of development.

Market

Therapeutic fusion vaccines can be used for most cancer indications, including haematologic cancers. Their expected benefits are expected to be in early stage indications, when the tumor load is not too large and the immune system in good condition to respond. Therapeutic vaccines are also expected to limit the rate of relapse. BruCells initially develops products against kidney cancer (renal cell carcinoma) and brain cancer (glioma), two significant unmet therapeutic needs for which there are no effective treatments. These indications qualify for orphan drug designation, which will accelerate the development and limit the costs. Once the proof of principle is established in one of these indications, additional indications will be developed.

Technology description

The products are based on the patented concept of fusion vaccines, which combine the superior antigen presentation capability of dendritic cells (DC) with the wide spectrum of tumour associated antigens present in cancer cells. They are expected to be more effective than other whole cell cancer vaccines or antigen specific vaccines currently under development. They are not subject to the limitations of other DC vaccines, because the dendritic cells used in the fusion are obtained from proprietary progenitor cell lines. By selecting the cancer cell lines, the concept can be used to treat most cancer indications, including haematological malignancies. The production can be made on inventory, without the use of any patient material or donor material, avoiding the constraints of autologous concepts.

State of the technology

- Development phase

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patents granted

Products description

- BCL004 is a fusion vaccine against renal cell carcinoma
- BCL003 is a fusion vaccine against glioma
- BCL005 is a fusion vaccine against melanome
- IL4 and GM-CSF are cytokines used in the production of cellular therapy products

Innovative aspects

The fusion concept of therapeutic vaccine is innovative and patent protected. The use of cell lines to produce dendritic cells is rather unique.

Research & Development

3 projects. Pre-clinical development on all 3 projects is almost complete (BCL004 - BCL003 - BLC005).

Type of partnership sought

- Financial resources
- Further research/development support
- Manufacturing/Subcontracting agreement

We are looking for partners for the development of additional cancer cell lines to be used in combination with our vaccines. This involves the sourcing and characterization of tumor biopsies and the development of cell lines from those under GMP conditions. We are also looking for partners for the scaling up of cell fusion and purification processes and for the cryopreservation of cellular products.

Type of partner sought

- Research institute
- Small to medium sized company
- University

Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)

Phone: +32 2 263 07 01
Fax: +32 2 263 07 09

E-mail
g.capart@brucells.com

Website
www.brucells.com

Contact person
Gilles Capart

Date of establishment
2001

Number of employees
6

Number of employees in R&D activities
4

Business model
Product provider

Activities in Brussels
Headquarter
R&D:research
R&D: pre-clinical development
R&D: drug discovery

BUSINESS DECISION LIFE SCIENCES

HEALTHCARE

CONSULTING ACTIVITIES - CONTRACT RESEARCH ORGANIZATION - SERVICE PLATFORMS

Rue Saint Lambert, 141
B - 1200 Brussels (Belgium)

Phone: **+32 2 774 11 00**
Fax: **+32 2 774 11 99**

E-mail
nicole.rensonnet@businessdecision.com

Website
www.businessdecision-lifesciences.com

Contact person
Nicole Rensonnet

Date of establishment
2007

Number of employees
117

Number of employees in R&D activities
110

Business model
Service provider

Turnover
8M €

Activities in Brussels
Headquarter
R&D: clinical development
Consulting, service platforms

Activities in other countries
R&D: clinical development
Biometry, clinical operations, systems validation, phase I unit
Switzerland, France, Tunisia, Israël

Corporate description

Business & Decision Life Sciences is a division of the Business & Decision group, an international consulting and system integration services provider with approximately 2700 employees worldwide. Business & Decision has offices in 19 countries in Europe, North America, Asia, North Africa and the Middle East.
The Life Sciences division is headquartered in Brussels, Belgium. Other offices of Business & Decision Life Sciences are situated in France (Paris), Switzerland (Zürich and Geneva), USA (Philadelphia), Israel (Tel Aviv) and Tunisia (Tunis). Tunisia hosts the offshore facility of Business & Decision Life Sciences. Business & Decision Life Sciences employs around 250 employees across the before-mentioned locations.
Business & Decision Life Sciences (B&D LS) offers a combination of skills, combining expert business process and regulatory knowledge as well as information technologies to leverage Life Sciences companies' response to an increasingly demanding clinical and regulatory environment.
Our strategy is based on being the best at what we do with the most qualified staff. Our promise to customers is to offer quality, excellence, detailed services on time and on budget. To this end, we are constantly evaluating our work and our staff, adjusting when necessary, and staying at the forefront of new developments.

Market

Pharma and biotech worldwide
Areas of Expertise: mainly biometry in the context of clinical trials, with a specific CDISC experience.
Our CDISC experience ranges from CDISC roadmap consultancy to regulatory submission preparation.
Below is a list of the CDISC services we provide:

- CDISC Data Conversions - For FDA submissions and for data warehousing
- CDISC Compliance Solutions
- Consultancy on CDISC Implementations at the clients' site:
  - Implementation plan/Conversion impact analyses, CDISC Roadmap
  - Data standards implementation, e.g: create metadata repository, implement SDTM /CDASH in a data management environment, etc
- CDISC SDTM Trainings
  - Private trainings hosted by sponsors and Public trainings hosted by the CDISC organization

Services description

The company operates three service lines:
Consultancy: the Consultancy services provide specialized expertise and/or additional resources at the sponsor's site.
CRO: the Contract Research Organization conducts end-to-end clinical studies projects in a regulatory compliant environment.
Service Platforms: the Service Platform model is similar to the consultancy model in that B&D Life Sciences consultants use the client's SOPs and systems, but work remotely from the B&D Life Sciences offices, providing increased flexibility for the client.
Our offering is as follows:
In Consultancy Mode (B&D LS consultant works at a sponsor's office): Clinical Trial Management, Data Management, CDISC implementation, Statistical Programming, Biostatistics, Medical Writing, Clinical Datawarehousing, Pharmacovigilance, Health Economics, Data Mining, Bio-Informatics, Clinical Applications, Business Intelligence, Computer Systems Validation.
In Platform Service Mode (B&D LS consultant works for a sponsor at B&D LS offices): Statistical Programming and Biostatistics.
In CRO Project Mode: CDISC Services Clinical Trial Management, Data Management, Statistical Programming, Biostatistics, Medical Writing.

Products description

Data Model Compliance Checker
This tool in conjunction with documented processes and procedures is used to:

- Validate data and metadata on CDISC SDTM V3.1.1 and V3.1.2 compliance
- Provides an easy to use interface for electing and running compliance checks
- Generates comprehensive exception reports
- Generating and validating CDISC compliant data sets can be a lengthy process. Our ata Model Compliance Checker helps resolve this intensively demanding process. The 600+ automated checks help identify and sometimes resolve data issues before the data is sent to the FDA. The tool is user friendly, flexible and has the functionality to import custom data models

Innovative aspects

This tool **"Data Model Compliance Checker"** allows to test the CDISC SDTM datasets and define.xml for their CDISC SDTM compliance before sending them to the FDA, resulting in a submission that enhances the use of the FDA reviewer tools and will not fail to load in the WebSDM tool.

CAF DCF RED CROSS

HEALTHCARE - INDUSTRIAL

THERAPEUTICS (PROTEINS, ANTIBODIES) - ANALYSIS LABORATORY - IMMUNE SYSTEM - INFECTIOUS DISEASES - HAEMOSTASIS - ALBUMIN

Corporate description

Central Department of Fractionation of the Red Cross (CAF-DCF): a mission in healthcare with the goal to improve the safety of supply in Europe of plasma-derived medicinal products from unpaid voluntary blood donors.

Mission

CAF-DCF is a not-for-profit organisation producing stable plasma derivatives such as clotting factor concentrates, immunoglobulin products, and albumin, destined for the treatment of diseases such as coagulation factor disorders, immunological diseases, and disturbances of the internal fluid balance. CAF-DCF has longstanding expertise in fractionation of plasma proteins. It manufactures medicinal products meeting the highest efficacy and safety standards.

Market

- Plasma products derived from plasma collected from Belgian donors are dedicated to Belgian patients
- Products derived from other countries are internationaly distributed

Technology description

Human plasma is the source material for manufacturing plasma products for therapeutic use under life-threatening conditions. Plasma derivatives are produced according to "state-of-the-art" pharmaceutical and biotechnological methods, including sophisticated purification techniques like chromatography and virus inactivation methods like nanofiltration. Biotechnology advances are implemented so as to meet the most stringent quality, safety, and efficiency requirements. In particular, virus testing is done by PCR (HIV, HBV, HCV, HAV, and erythrovirus (former parvovirus) B19. Patients suffering from rare disorders due to a lack of active plasma proteins (Factor VIII, Factor IX, fibrinogen, von Willebrand Factor, C1-inhibitor, IVIG, etc) can be treated efficiently with our plasma products.

In 1998, CAF-DCF formed an alliance with its Dutch sister organisation, Sanquin-CLB, located in Amsterdam. In 2008, a wide-ranging agreement with the French state-owned biopharmaceutical group LFB. In addition, CAF-DCF has collaborated with sister organisations and European technological partners.

New production facilities

Since 2004, a new "state-of-the-art" plant with a capacity of more than 700,000 litres of plasma, to be fractionated into intermediate bulk fractions, has been in activity in Brussels-North. CAF-DCF fractionates plasma collected in Europe and in the US in addition to all the plasma collected by Belgian transfusion centres. CAF-DCF is FDA approved after two extensive inspections in 2007 and 2008.

State of the technology

- Already on the market
- Development phase

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patents applied - not granted
- Patents granted

Products description

- Pharmaceutical protein concentrates
- Immunodeficiency/autoimmunity/infectious diseases/clotting factors/albumin

Innovative aspects

- Virus screening techniques using nucleic acid technologies and neutralisation by specific antibodies
- New and standard virus inactivation technologies
- Protein purification and characterisation
- Immunoglobulin specificities and properties
- Expertise in plasma proteins; clotting factors
- Clinical studies

Type of partnership sought

- Further research/development support
- License agreements
- Manufacturing/Subcontracting agreement
- Transfer of know-how

Avenue de Tyras, 109
B - 1120 Brussels (Belgium)

Phone: +32 2 264 64 11
Fax: +32 2 262 27 31

E-mail
ruth.laub@caf-dcf-redcross.be

Website
www.caf-dcf.redcross.be

Contact person
Ruth Laub

Date of establishment
1998 (former CAF-DCF Belgian Red Cross)

Number of employees
183

Number of employees in R&D activities
5

Business model
Product provider

Activities in Brussels
Headquarter
R&D: research
R&D: pre-clinical development
R&D: drug discovery
R&D:clinical development
Manufacturing
Marketing
Distribution
Toll plasma fractionation

CAF-DCF
your partner for stable plasma derivatives

CATALENT PHARMA SOLUTIONS

HEALTHCARE

SERVICE PROVIDER - STERILE MANUFACTURING

Font Saint Landry, 10
B - 1120 Brussels (Belgium)

Phone: **+32 2 788 50 00**
Fax: **+32 2 788 39 59**

E-mail
sales@catalent.com

Website
www.catalent.com

Contact person
Jerome Detreille
Sales contact

E-mail
Jerome.detreille@catalent.com

Number of employees
395

Business model
Products & Service provider

Activities in Brussels
Development
Sterile manufacturing
Secondary packaging
Distribution

Activities in other countries
Headquarter
Sterile manufacturing
Oral technologies
Packaging
Development & clinical services
USA,UK, France, Argentina, Brazil, Italy, Germany, Switzerland, Australia, Japan

Corporate description

Catalent Pharma Solutions is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes.

Technology description

Catalent Group

Development
Catalent offers a full range of development services, such as pre-clinical support, API development, analytical services, drug delivery development, clinical manufacturing and packaging services.

Manufacturing
We provide manufacturing for nearly every major dose form on the market today. Along with our proprietary dose forms, we also manufacture traditional oral, sterile and inhaled dose forms. We also produce biologics for pre-clinical and clinical studies.

Packaging
Catalent is the largest provider of packaging services to the pharmaceutical industry. Our packaging services include commercial packaging for all dose forms and the supply of printed components. We specialize in new product launch support and are the recognized leader in the packaging of biotechnology products, and the design and development of innovative compliance packaging and novel unit-dose formats.

Services description

Catalent Belgium (Brussels)

- Sterile compounding of pharmaceutical products
- Sterile pre-filled syringe filling 0,5 - 20 ml
- Terminal sterilization
- Secondary packaging

CHEMCOM

AGROFOOD - ENVIRONMENT - HEALTHCARE - INDUSTRIAL

DRUG DISCOVERY/SCREENING - MOLECULES SUPPLIER - DIAGNOSTIC TOOLS - TECHNOLOGY PROVIDER

Corporate description
ChemCom is dedicated to become a major player in the discovery of products and tools relevant to chemosensory technologies: e.g. taste, olfaction and other sensory modalities. ChemCom offers products and services to food, cosmetic, agricultural, industrial, pharmaceutical and biomedical industries.

Market
Cosmetic, agriculture, food industries as well as health (drug and environmental) industries.

Technology description
Use of molecular and cellular biology of receptors (GPCR) to discover new molecules (agonists, antagonists and enhancers) such as new fragrance, malodor blockers and insecticides.

State of the technology
- Available for demonstration
- Development phase



Intellectual Property Rights (IPR)
- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patents applied - not granted
- Patents granted

Products description
Deodorant, freshener.

Innovative aspects
Only the in vitro approach will provide new and relevant informations leading to the identification and/or the design of new molecules: new odors, blockers of malodors, etc.

Research & Development
4 projects. Molecules in development.

Type of partnership sought
- Joint venture agreement
- License agreements
- Manufacturing/Subcontracting agreement

Chemcom is looking for companies specialized in fine chemistry in relation to flavour, fragrance and food and for companies active in research, production and selling of the final products: house care, cosmetics, drugs, pesticides, etc. Research partnership, technological partnership, commercial partnership with technical assistance, other.

Type of partner sought
- Small to medium sized company
- Large company
- Research institute
- University

Route de Lennik, 802
B - 1070 Brussels (Belgium)

Phone: +32 2 529 00 14
Fax: +32 2 529 81 41

E-mail
info@chemcom.be

Website
www.chemcom.be

Contact person
Christian Van Osselaer

Date of establishment
2000

Number of employees
19

Number of employees in R&D activities
19

Business model
Product & Service provider

Activities in Brussels
Headquarter
R&D: research
R&D: pre-clinical research
R&D: drug discovery

ChemCom

CLINEURODIAG

ENVIRONMENT - HEALTHCARE - INDUSTRIAL

DIAGNOSTIC TOOLS - GENETIC ANALYSIS/PHARMACOGENOMIC - BIOMARKERS - BIOCHIPS - CONSULTING ACTIVITIES (TECHNICAL ADVICES) - INFECTIOUS DISEASES - RESPIRATORY DISEASES

Clos Chapelle aux Champs, 30
BP 30.46
B - 1200 Brussels (Belgium)

Phone: **+32 2 764 31 56**
Fax: **+32 2 764 39 59**

E-mail
d.talibi@live.be

Contact person
Driss Talibi

Date of establishment
2009

Business model
Product & Service provider

Activities in Brussels
R&D: research
Manufacturing

Corporate description

ClinEuroDiag is an innovative company specialized in Molecular Diagnostics, genetic signatures analysis (DNA / RNA) and isolation of new genetic markers. ClinEuroDiag's main objective is to become the market leader in genomics applications and to extend their activities in the area of molecular diagnostics in Europe by means of the design, development and commercialization of new diagnostic applications with its innovative in vitro diagnosis platform, "ClinDiag Arrays". ClinEuroDiag manufactures, and markets Microarrays that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. ClinEuroDiag's Microarray service provides complete MicroArray solutions, from probe design, oligonucleotides production, PCR amplification and Microarray manufacturing to complete gene profiling service including cDNA synthesis and labelling, hybridisation and data analysis, for academic and industrial customers. Through collaborations with academic laboratories and European consortiums (Galar fungal, Garnish, StrepSec), our DNA array service has developed MicroArrays for bacterial and fungal niche (H.Pylori, B. subtilis, N. meningitides, L. lactis, C. albicans, S. cerevisiae, S. pombe, Y. Lypotica...).

Market

Current molecular diagnostics are primarily single-analyte tests involving the detection of a single gene or protein. However, many disease-related processes are multifactorial, involving the abnormal expression of multiple genes or proteins. Second-generation molecular diagnostics are anticipated to utilize novel detection technologies and multiplexing platforms to allow the measurement of a large number of analytes simultaneously. These innovations will increasingly utilize multiplexing platforms such as DNA microarrays that perform parallel biomarker analyses. There are indications that the next advance will involve measuring several biomarker types simultaneously. Such innovations relate to constructs, such as DNA/antibody microarrays capable of assaying proteins and nucleic acid test simultaneously.
ClinEuroDiag targets laboratory-based immunoassay and nucleic acid test such as hospitals and clinical laboratories.

State of the technology

- Development phase

Services description

Pharmacogenomics
Sample bio-banking, High throughput DNA extraction, purification, and quantification. Pharmacogenomic sequencing and expression profiling, Genotyping panel development, Genotyping panel screening and validation, Diagnostic product development, Search for genetic markers, Supply of molecular diagnostic testing.

Genotyping
Microsatellite genotyping (for genome-wide scans and fine mapping), Single Base Extension SNP genotyping, Allele specific hybridisation.

Functional Genomics
RNA quality testing, Labeling and hybridization Microarrays, Validation services by RT-PCR, Statistical staff for simple analysis help and advanced analysis services.

Genomic MicroArray
Custom MicroArray fabrication services, Bioinformatic services for PCR primers designs and oligonucleotide probes for MicroArrays, Synthesis of oligonucleotides from 15 bases to 70 bases, and the incorporation of different modified nucleotide: amino link, LNA, Wobble, inosine, etc. Different chemistry of DNA attachment to the surface support, Printing and manufacture of oligonucleotide microarray and PCR products.

Production of catalogue DNA microarrays
B. subtilis, L. lactis, N. meningitidis, S. Pneumoniae, S. lividans, C. albicans, S. pombe, Y. Lipotlyic.

Innovative aspects

ClinEuroDiag will use advances in molecular techniques, such as Microarrays and Real-Time PCR, to develop a range of assays for the rapid, accurate and sensitive detection of bacteria and fungi such as Aspergillus spp., Pneumocystis jirovecii and Candida spp. Evidence shows that an early diagnosis of invasive fungal infection significantly improves the chance of survival. Tests provided by ClinEuroDiag will aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease reduces the patient's exposure to inappropriate drug treatments, improves patient outcomes and reduces the hospitalisation and treatment costs associated with invasive fungal disease.

Research & Development

3 projects in first stage of development.

Type of partnership sought

- Distribution agreement
- Transfer of know-how

Type of partner sought

- Small to medium sized company

DE VALCK CONSULTANTS

AGROFOOD - HEALTHCARE - INDUSTRIAL

CONSULTING ACTIVITIES (REGULATORY AFFAIRS, TECHNICAL ADVICES)

Corporate description

Since 2005, De Valck Consultants exclusively focuses on delivering Quality Assurance consulting services. With more than 130 consultants and 5 offices in Europe, we are the European partner for the Life Sciences industry: Pharma & Biotech, Medical Technologies and Health & Nutrition.

De Valck Consultants is the dedicated brand to Quality Assurance of the Altran Group for the Life Sciences industry.

Technology description

Consulting services.

State of the technology

- Already on the market

Services description

Pharmaceutical and biotechnology consulting services:

- Quality Assurance
- Audit
- From Engineering to Validation

Type of partnership sought

- Manufacturing/Subcontracting agreement

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University

Avenue de Tervuren, 142/144
B - 1150 Brussels (Belgium)

Phone: **+32 2 737 68 68**
Fax: **+32 2 737 68 88**

E-mail
pharma@devalckconsultants.com

Website
www.devalckconsultants.com

Contact person
Fabrice Dekoninck

Date of establishment
1989 (Company)
2005 (Life Sciences Division)

Number of employees
800 (Company)
130 (Life Sciences division)

Business model
Service provider

Turnover
14 M€
(2009 for Life Sciences Division)

Activities in Brussels
Headquarter

Activities in other countries
Consulting services
France, Ireland, Switzerland

De Valck Consultants

ECCRT

EUROPEAN CENTRE FOR CLINICAL RESEARCH TRAINING

HEALTHCARE

TRAINING & COACHING OF PROFESSIONALS IN CLINICAL R&D - ALL AREAS OF CLINICAL OPERATIONS, REGULATIONS AND SOFT SKILLS

Keizer Karellaan, 576 - box 4
B - 1082 Brussels (Belgium)

Phone: **+32 2 464 39 55**
Fax: **+32 2 465 56 23**

E-mail
info@eccrt.com

Website
www.eccrt.com

Contact person
Veerle Bultinck

Date of establishment
2000 as a part of HCR Benelux
2009 as an independent company

Business model
Service provider

Activities in Brussels
Headquarter
Training & Coaching for professionals in clinical R&D

Activities in other countries
Training & coaching for professionals in clinical R&D in Europe and overseas

European Centre for Clinical Research Training

Corporate description

The "European Centre for Clinical Research Training" is a division of the Harrison Clinical Research Group and the primary focus is to serve as a training centre for professionals in the pharmaceutical, biotechnological and academic clinical research environment.

The courses offered are tailored to every level of experience and are divided into modules ranging from an introduction course over clinical research and monitoring, to current regulatory requirements of clinical trials and specific medical research areas such as the development of vaccines or understanding the ECG trace in cardiology trials.

In addition, ECCRT also provides tailored courses, specifically designed to company training needs and given on-site at the company or institution.

Market

Over the last ten years the company has provided training all over the world, for small and global companies and for different levels of profiles.

The customers of the European Centre for Clinical Research Training (ECCRT) are pharmaceutical, biotech, medical device and neutraceutical companies, as well as private persons, freelancers, academics, researchers and hospital staff.

Technology description

Recent Training Techniques such as Interactive Voting Software, etc.

State of the technology

- Available for demonstration

Intellectual Property Rights (IPR)

- Exclusive rights

Services description

Service in Clinical Research:
training & coaching

Products description

- Training and Coaching Services on Clinical Operations
- Clinical Operations Related Topics and Soft Skills for Professionals in clinical R&D

Innovative aspects

- Dedicated & professional trainers
- Interactive trainings

Type of partnership sought

- Partnerships on educational level, implementation of training

Type of partner sought

- Small to medium sized company
- Large company
- Research institute

EUROSCREEN

HEALTHCARE

THERAPEUTICS (SMALL MOLECULE) - DRUG DISCOVERY/SCREENING - MOLECULES SUPPLIER - CONTRACT RESEARCH ORGANIZATION - TECHNOLOGY PROVIDER - CNS - DIABETES - DIGESTIVE DISEASES - INFLAMMATION

Corporate description

Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, Euroscreen is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as GPR43 or CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.
Euroscreen pursues a dual business model strategy of combining:

- Its internal programs on high value targets (Euroscreen DRUG DISCOVERY)
- With its fully dedicated Business Unit (Euroscreen FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world

Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Novartis and Pfizer.

Market

Partnership with Pharmas, worldwide.

Technology description

GPCR expert, track-record on New Chemical Entities drug discovery for unmet medical needs.
Euroscreen give access through partnership to its novel and proprietary drug candidates, and Euroscreen Fast Busniness Unit is providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

State of the technology

- Development candidate stage
- Marketed activities for services

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Subcontractual agreement
- Patents applied - not granted
- Patents granted

Services description

Euroscreen Fast Business Unit providing customized screening, profiling and assay development on all the GPCRs including orphans.

Products description

Novel and proprietary chemical series for unmet medical needs.

Innovative aspects

- Proprietary targets
- Research & Development platform
- Proprietary New Chemicals Entities

Research & Development

4 to 6 projects. More advanced are optimized lead series with in vivo proof of concept ready to go in drug development.

- GPR43 Modulator project
- ESN-280: Diabetes/Dyslipidemia, Lead optimized stage
- ESN-295: Ulcerative Colitis, Lead optimized stage
- NK3 Antagonist project
- ESN-413: Schizophrenia/cognitive disorders, Lead optimized stage
- ESN-428: Endometriosis/prostate hyperplasia, Lead optimized stage

Discovery Projects:

- GPR131 Agonist: Diabetes/obesity, Hit to Lead stage
- GPR35 Agonist: Inflammation/Immunomodulation, Hit to Lead stage
- GPR3 Modulators: Alzheimer's/cognitive disorders, Hit to Lead stage

Type of partnership sought

- Financial resources
- License agreements

Type of partner sought

- Small to medium sized company
- Large company

Route de Lennik, 802
B - 1070 Brussels (Belgium)

Phone: +32 71 348 500
Fax: +32 71 348 519

E-mail
info@euroscreen.com

Website
www.euroscreen.com

Contact person
Jean Combalbert, Ph D

Date of establishment
1994

Number of employees
49 (in Brussels 8 to 10)

Number of employees in R&D activities
38 (in Brussels 8 to 10)

Business model
Product & Service provider

Activities in Brussels
Headquarter

Activities in other countries
R&D: research
R&D: pre-clinical development
R&D: drug discovery
All over the world through partners or on our own.

EUROSCREEN

FETON INTERNATIONAL

HEALTHCARE

DRUG DELIVERY - MANUFACTURER OF CAPSULE FILLING, LOADING, COATING, BLISTERING DEVICES

Rue Gabrielle Petit, 4 b9
B - 1080 Brussels (Belgium)

Phone: **+32 2 420 52 00**
Fax: **+32 2 420 61 61**

E-mail
fetonrve@netscape.net

Website
www.feton.com

Contact person
Richard Van Elewyck

Date of establishment
1973

Number of employees
5

Number of employees in R&D activities
2

Business model
Product provider

Turnover
+/- 900K €

Activities in Brussels
Manufacturing
Production
Distribution/Sales

Activities in other countries
Distribution
USA, Canada, CEE, East Europe distributors

Corporate description

For decades Feton, a small and dynamic company, serves the pharmacist's expertise. Inventor of the small capsule filler, Feton has developed a complete processing system for hard gelatin capsules. With Feton, one can load, fill, coat and blister pack capsules.

Feton manufactures and distributes pharmaceutical and para-pharmaceutical products such as:

- Feton Capsule Filling and Loading machines, enabling the filling of empty capsules in series of 60, 100, 120, 200 or 300 capsules
- Feton enteric coater, enabling the preparation of gastro-resistant capsules
- Feton empty capsules sizes 000, 00, OE, 0,1,2,3,4 and 5

Owing to a highly specialized network, Feton International is the leader in the field of empty Capsules distribution in Belgium.

Feton International enjoys an excellent reputation due to the superior quality of its products and its excellent service both in Belgium and Internationally Feton's international activities are backed by a distribution network characterized by longlasting and efficient commercial partnerships with foreign importers, wholesalers and distributors.

Technology description

Semi-automatic, user friendly kits for capsule filling, coating and blistering.

State of the technology

- Already on the market

Innovative aspects

Easy to use, low maintenance, high level material, fast and economic way to fill small batches of capsules.

Research & Development

1 project. Development of new capsule filler 400 caps.

Type of partnership sought

- Distribution agreement

Type of partner sought

- Small to medium sized company

GENTAUR

HEALTHCARE

MOLECULAR PRODUCTS (DNA, RNA, PROTEINS, ANTIBODIES, SMALL MOLECULES) - CELL CULTURE EXPERTISE - IN-VITRO DIAGNOSTICS

Corporate description

GENTAUR is supplier in life sciences reagents, services, storage and invoicing, we occupy 1200 m² fulfillment in Brussels airport.

Technology description

GMP E.coli recombinant human IL-4, GM-CSF, TNF-a,IL-1B, IL-6 CD40L for dendritic cell culture, IL-2,HIV,p24 ELISA,Melanomax for melanocytes culture, Vitotox, synoviocytes, chondrocytes,Cholera toxin, immunohistomax, antibodies production, protein purification, mouse caspases, Pt7pol plasmid & tissue arrays.

Services description

Provider/Supplier

Innovative aspects

Personalized online ordering and web based access to sample storage -80C°, -20C° and 2-8C°.

Type of partnership sought

- Distribution agreement
- Manufacturing/Subcontracting agreement
- Transfer to know how

Avenue de l'Armée, 68
B - 1040 Brussels (Belgium)

Phone: **+32 2 732 56 88**
Fax: **+32 2 732 44 14**

E-mail
lieven@gentaur.com

Website
www.gentaur.com
www.diagrade.com

Contact person
Lieven Gevaert

Date of establishment
1999

Business model
Provider/Supplier

Activities in Brussels
Headquarters
Distribution

Activities in other countries
France, Germany, Poland, Italy

GMP E.coli recombinant human IL-4, GM-CSF, TNF-a, IL-1B, IL-6 CD40L for dendritic cell culture, IL-2,HIV,p24 ELISA,Melanomax for melanocytes culture, Vitotox, synoviocytes, chondrocytes,Cholera toxin, immunohistomax, antibodies production, protein purification , mouse caspases, Pt7pol plasmid & tissue arrays

GENTAUR

HARRISON CLINICAL RESEARCH BELGIUM

HEALTHCARE

CONTRACT RESEARCH ORGANIZATION - DATA MANAGEMENT FOR CLINICAL RESEARCH - SCIENTIFIC CONSULTANCY - QUALITY SERVICES - MEDICAL WRITING TRAINING -OUTSOURCING SERVICES - CONSULTING ACTIVITIES (REGULATORY AFFAIRS, TECHNICAL ADVICES) - CLINICAL OPERATIONS - TRANSLATIONS - IMP SERVICES - STATISTICAL ANALYSIS

Keizer Karellaan, 576
B - 1082 Brussels (Belgium)

Phone: +32 2 464 39 00
Fax: +32 2 465 56 23

E-mail
werner.stilmant@harrison.be

Website
www.harrisonclinical.com

Contact person
Werner Stilmant

Date of establishment
1996

Number of employees
45

Number of employees in R&D activities
36 in Clinical Operations, Quality Services, Regulatory Affairs and Medical Writing

Business model
Service provider

Activities in Brussels
R&D: clinical operations including project management and global monitoring - Outsourcing, Regulatory Affairs, Quality Services and Medical Writing, Training, Translations, IMP Services

Activities in other countries
Headquarter
R&D: clinical operations including project management and global monitoring - Outsourcing, Regulatory Affairs, Quality Services, Training, Medical writing, Translations, IMP services
Biometrics Department (Data Management, Statistical Analysis), Quality management department, scientific consultancy, Clinical Unit (Phase I Unit) all located at Harrison Clinical Research HQ in Munich, Germany, Austria, France, UK, Italy, Spain, Poland, Ukraine, Russia, Israël, US, Japan

Corporate description

Harrison Clinical Research Benelux nv is part of the Harrison Clinical Research Group founded in 1987 by Dr Francisco Harrison.

The company offers a full service solution for clinical research projects, both globally and locally. The activities range from phase I - IV studies and trials are conducted in accordance with all international and local regulatory requirements.

Market

Over the last twenty-three years the company has conducted studies covering all major therapeutic areas and all classes of products.

The clients of Harrison Clinical Research are pharmaceutical, biotech, medical device and nutraceutical companies. Harrison Clinical Research is represented by own local offices in Belgium, Germany, France, UK, Austria, Italy, Spain, Poland, Ukraine, Russia, Israel and the US. The headquarters in Munich (Germany) has its own Phase I Unit, available for early phase clinical development.

Services description

Harrison Clinical Research offers the following services for clinical research: clinical operations (including CRA, PM and CTA outsourcing services), Regulatory and Scientific Advice, International Project management and Monitoring Services, Quality Management, Auditing, Data Management, Biometrics, Training, Medical Writing and Translating.

Innovative aspects

Harrison Clinical Research is an international CRO offering a full service solution for clinical research projects, focusing on achieving the highest quality by constantly providing training to the staff and by implementing lean operations concepts. This approach resulted in a successful audit of the headquarters by the FDA in 2009.

Type of partnership sought

- Further research/development support
- Clinical research support

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University
- Biotechnology
- Pharmaceutical
- Nutraceutical
- Medical Device companies

HM3A

HEALTHCARE

CONSULTING ACTIVITIES (REGULATORY AFFAIRS, MARKET ACCESS, TECHNICAL ADVICES) - ALL THERAPEUTICS FIELDS

Corporate description

Based in Brussels, Belgium, in the heart of Europe, HM3A is an independent specialist consultancy specialized in market access for pharmaceuticals and medical devices. We are committed to deliver value and quality through objective and effective advice to clients on all matters related to obtaining and maintaining access to market in Europe.

Our small core of four partners, accrued, together, more than 100 years of experience and expertise. We work with a few very experienced consultants. Through our network we work with leading experts in strategically important fields.

HM3A is a one-stop shop to bring you and your products to market from A to Z!

Market

Pharmaceuticals and Medical Devices.

Services description

- Medical, regulatory, market access and commercialization strategy
- Regulatory Affairs
- Governmental and Public Affairs
- Early market access
- Pricing and Reimbursement by Public Health Insurance
- Business development

Innovative aspects

Our small core of four partners, accrued, together, more than 100 years of experience and expertise. We work with a few very experienced consultants. Through our network we work with leading experts in strategically important fields.

Type of partnership sought

- Companies looking for market access specialists

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University

Avenue Joseph Wybran 40
B - 1070 Brussels (Belgium)

Phone: **+32 529 58 62**
Fax: **+32 2 461 03 03**

E-mail
marc.czarka@hm3a.eu

Website
www.hm3a.eu

Contact person
Marc Czarka

Date of establishment
2008

Number of employees
4

Business model
Service provider

Activities in Brussels
Headquarter
Consultancy

Activities in other countries
Consultancy in EU

IDRABEL

ENVIRONMENT

POLLUTION TREATMENT

Rue St Denis, 51
B - 1190 Brussels (Belgium)

Phone: +32 2 345 42 53
Fax: +32 2 345 64 81

E-mail
f.deswattines@idrabel.com

Website
www.idrabel.com

Contact person
Frédéric Deswattines

Date of establishment
1996

Number of employees
6

Business model
Product & Service provider

Activities in Brussels
Headquarter
R&D: research
Manufacturing
Marketing
Distribution

Activities in other countries
Distribution

IDRABEL
ENVIRONMENTAL BIOTECHNOLOGY

Corporate description

Since 1996, IDRABEL is an European biotechnology company which develops and supplies products to treat all industrial and municipal organic pollution in water

With more than 100 references in area as diverse as sewage network, lakes, canals, environmental, food, paper and petro-chemical industries, our technical team have a long experience to work in collaboration with our customers to design specific solution to reach concrete and measurable results.

Our main product ranges, BIO-COL, BIO-EPUR and BIO-VASE offer a global solution in waste water treatment.

Market

Breaks down sludge and grease deposits, stop odours and treatment of specific organic pollution in sewer networks, collectors, Municipal and Industrial waste water treatment plant.
Our clients are Water and Wastewater services company, administration, environmental company, industry, etc.

Technology description

IDRABEL offers a range of natural biotechnological products covering the full waste water treatment based on a process called Biofixation which fixes natural micro-organisms on mineral supports. An efficient, economical and environmentally friendly approach.

The advantages of the Biofixation are to: have a high percentage of micro-organism reactivation:

- protects the micro-organisms in highly polluted environment
- increase their growth
- improve the effectiveness
- rehabilitate a viable ecosystem
- enable a mix of micro-organisms in order to obtain specific products

State of the technology

- Already on the market

Services description

Idrabel provide a range of integrated services to private and public sector. Our effective and sustainable approach of wastewater treatment and environment management includes: research, development, consultancy, training, testing, supervision, operation, maintenance.

Products description

Our main product ranges, BIO-COL, BIO-EPUR and BIO-VASE offer a global solution in waste-water treatment.

BIO-COL: treatment of all municipal waste-water & sewage, the sewer networks and collectors.

BIO-VASE: degradation of organic sludge, biodregging of canal, river, lakes, and marine ports, harbors and lagoons.

BIO-EPUR: treatment of all municipal and industrial wastewater treatment plant.

Innovative aspects

IDRABEL is characterized by the following strengths:

- Experienced management and team
- Leading biotechnology innovative applications
- Hundreds references and measurable results
- Developed strong and long-term relationships with customers
- Cost effective and cost saving
- Designed specific products
- Exellence in safty, health and environmental performance
- High-quality and flexible production

Research & Development

1 project in final stage. Bioinsecticide to destroy mosquito larvae.

Type of partnership sought

- Distribution agreement

Type of partner sought

- Small to medium sized company

IMBP

ENVIRONMENT

POLLUTION TREATMENT - PRODUCER OF MICROBIAL CONSORTIUM FOR ENVIRONMENTAL TECHNOLOGY

Corporate description

Created in 2002, IMBP is a spin-off of the Meurice Institute (Biotechnology Unit). IMBP activities (production, R&D) are subcontrated to the non-profit association of the institute, Meurice R&D. The owners are Meurice R&D and researchers from the Meurice Institute.

Market

Market

Environmental technology involving bio-augmentation.

Type of clients

Industrial partner dealing with biological products for environmental technology - developer of formulations for septic tank treatment and wastewater treatment - manager of wastewater treatment plant.

Technology description

Production of specific microorganisms for environmental technology - well adapted formulations.

State of the technology

- Already on the market

Products description

The purpose of IMBP is the production and marketing of micro-organisms specific to environmental technology ("bioaugmentation").

IMBP has developed highly concentrated and stabilized micro-organisms (Bacillus spores, Pseudomonas...) formulations for waste water treatment.

Spores of Bacillus have been successfully tested in septic tank treatment, wastewater treatment plants and composting. Technical collaboration is sought with industrial partners dealing with biological products and ideally possessing mixers and packaging units.
The company is proposing three preparations including spores of Bacillus - two solid (powdered or encapsulated) and a liquid one.

The spores concentrations are certified in the formulations as follows:

- for liquid formulation: 2.10 E+10 CFU/ml
- for dry formulation: 1.10 E+11 CFU/g
- for encapsulated formulation 1.10 E+9 CFU/g

These natural and biodegradable products present a very high-concentration biomass and their viability is maintained at 100% for extended periods (shelf life up to 5 years) when compared to traditional solutions. According to their specific bioactivity, these products accelerate the biodegradation rates up to 20%.
Moreover, the advantage of encapsulation is the delaying effect of bacterial action. Thanks to encapsulation, bacteria are gradually released, which is particularly recommended for devices that need continuous maintenance.

Innovative aspects

- These products are very concentrated (up to 1.10 E+11 CFU/g)
- These products contain a mix of different strains presenting a large panel of enzymatic activities
- These products are stable and with extended shelf life (up to 5 years)

Main Advantages

- Volume reduced for transportation as a result of to the high-concentration biomass of these products
- High specific bioactivity for organic matters biodegradation as protein, starch, cellulose, lipids... (It accelerates the biodegradation rates up to 20%)
- Standard and customized biological starters
- Biodegradable, natural, adapted for environmental purposes

Type of partnership sought

- Distribution agreement
- Further research/development support

Type of partner sought

- Small to medium sized company

Avenue Joseph Wybran 40
B - 1070 Brussels (Belgium)

Phone: +32 2 526 73 71
Fax: +32 2 526 73 88

E-mail
a.durieux@meurice.ubt.be

Website
www.imbp.be

Contact person
Alain Durieux

Date of establishment
2002

Business model
Product provider

Activities in Brussels
Headquarter

LABIMA

HEALTHCARE - INDUSTRIAL

MANUFACTURING SERVICES (CMO) - LOGISTICS FOR CLINICAL RESEARCH - ALLERGY - INFLAMMATION - RESPIRATORY DISEASES

Avenue Van Volxem, 328
B - 1190 Brussels (Belgium)

Phone: +32 2 349 03 00
Fax: +32 2 345 30 48

E-mail
info@labima.com

Website
www.labima.com

Contact person
Jacqueline Siméons

Date of establishment
1956

Number of employees
19

Number of employees in R&D activities
2

Business model
Product & Service provider

Turnover
2 Mio €

Activities in Brussels
Headquarter
Manufacturing
Marketing
Distribution

Corporate description

Labima, a 100% family owned company, created in Brussels (Belgium) in 1952.
Labima is a pharmaceutical company of which the main activities are:

- Manufacturing packaging of pharmaceutical specialities: i.e. tablets, caps, solutions and emulsions, according to GMP
- Storage & distribution of products according to GDP
- Distribution & promotion to pharmacists, as well as to the medical profession, in BeLux
- Development of new galenic formulations
- Packaging, labelling, release storage and distribution of investigational products for clinical trials according to annex 13 and directive 2001/20/EC

Mission

- Develop, manufacture and supply products with a permanent care for quality, total service, respect for the persons in conformity with national and European standards, and in a profitable way.

Labima has 3 axes of development:

- Through his own set of products both in Belgium and abroad (inside and outside EU)
- Through outsourcing services for products on the market (Belgium and abroad): i.e. Production, Packaging, Storage, Distribution, etc
- Through GMP services to third parties for product in clinical trial phases (I up to IV))

Market

Our clients

- Belgian, EU and non EU pharmacists and wholesale
- Other pharmaceutical organisations from SME up to large International companies
- CRO's, Biotech and Pharma Research Organizations

Technology description

- Production of pharmaceutical products: tablets, capsules, solutions, creams and ointments
- Packaging, of pharmaceutical products: blisters (alu/alu & alu/polymer), boxes, tubes, bottles, strips, syringes, etc
- Storage and distribution of pharmaceutical products
- Distribution of products to pharmacists and wholesales
- Exportation of products within and out of EU
- Any GMP related services in Clinical Trials from phase I up to Phase IV

State of the technology

- Already on the market

Services description

Fields of action: Labima covers the whole set of activities of any pharmaceutical company.

- R&D: mainly in galenic and in cooperation with Belgian universities
- Clinical Trials: GMP services and logistic for third parties
- Production: Labima's own product set and for third parties
- Packaging: Labima's own product set and for third parties
- Quality Control: for any product entering or leaving the company
- Quality Assurance: for any task from order up to shipping
- Storage: in clean and approved warehouses at room and controlled (low) temperatures
- Distribution: in Belgium, Europe and outside EU

Products description

- OTC Registered drugs
- Ethic Registered drugs
- Medical Devices

Innovative aspects

Our innovative skills are mainly oriented to galenic developments for both our own product set and for our contracting clients. We are also able to perform productions tasks requiring very specific equiment or using very specific methods currently not applicable in large production units for both financial and technical reasons.

Type of partnership sought

- Distribution agreement
- Financial resources
- Further research/development support
- Joint venture agreement
- License agreements
- Manufacturing/subcontracting agreement
- Transfer of know-how

We are in a fast manufacturing development process and we have acquired products, persons and technology to achiev this goal. The Economic Development Unit (SRIB) of the Brussels region is assisting us in the project. Therefore we are looking for new projects in both manufacturing and clinical research services area.

Type of partner sought

- Research Institute
- Small to medium sized company
- University

LCA (LABORATOIRE DE CONTRÔLE ET D'ANALYSE)

HEALTHCARE

ANALYSIS LABORATORY - CONSULTING ACTIVITIES (REGULATORY AFFAIRS, MARKET ACCESS, TECHNICAL ADVICES)

Corporate description

LCA Ltd is, since 1983, a testing laboratory as well as a service and consultancy company located in the Brussels area.

LCA Laboratory

The LCA laboratory follows the ISO 17025 and is active in the chemical, physicochemical, bacteriological and toxicological fields.

This quality system allows LCA to be registered in various domains:

- by the Department of Pharmacy Inspection of the Ministry of Health, for drug testing in Belgium and Europe
- by the Ministry of Health, for the control of biocides (hospital and surface disinfectants)

LCA Consultancy

As a consultancy company, LCA has developed her activity in the following domains:

- Within the pharmaceutical field, in Regulatory Affairs (R.A.), by helping Belgian and foreign pharmaceutical companies in administrative, pharmaceutical and clinical steps for the working-out and follow-up of drug dossiers, according to both the Belgian and European Procedure

  For example:
  - Writing and compilation of full CTD registration files for abridged bibliographical or generic applications
  - Writing and compilation of CMC sections of CTD registration files
  - Writing and compilation of Type IA, Type Iain, Type II, and Line extensions registration files
  - Writing and compilation of renewal applications
  - Responsibility as Qualified Person pursuant to 2001/83/EC art 51 or art 103
  - Responsibility for advertising and information pursuant to Royal Decree April 7th, 1995, art 13
  - Translation of scientific texts (pharmaceutical, medical and parapharmaceutical fields)
  - Writing and compilation of full CTD registration files for new medicinal products
  - Writing and compilation of Clinical Trials applications, including IMPD section
  - Consultancy and overall regulatory strategic support in development plans and life cycle management for new or existing drugs
  - Regulatory support during due diligences
- Within the scope of pharmaceutical engineering, through counselling and support in accordance with Good Manufacturing Practice (GMP) and the validation of pharmaceutical premises or manufacturing processes
- In the field of cosmetics and foodstuffs by helping in the information, training, audit, and follow-up of companies in HACCP plan
- Control of content of specifications including technical, scientific and legal aspect for great distribution

Vision

To implement all its services and tasks, LCA has set up a team and a laboratory structure where pharmacists and scientists work under the responsibility and control of heads of departments and of a Quality Assurance Adviser.

Ethics

Our duties are achieved based on confidentiality (Secrecy agreement) which guaranties discretion to our customers as required by the Belgian law of 22/09/66.

Market

European and non-European pharmaceutical companies.

Technology description

Microbiological and analytical fields.

State of the technology

- Already on the market

Innovative aspects

- Accredited by the Belgian FAMHP
- GMP compliant

Research & Development

4 projects in product development. Optimalization of injectable drugs.

Type of partnership sought

- Joint venture agreement
- Transfer of know-how

Type of partner sought

- Small to medium sized company

Avenue Jean Jaurès, 46
B - 1030 Brussels (Belgium)

Phone: +32 2 215 04 01
Fax: +32 2 216 01 53

E-mail
ra@lca.be
seppe.degelas@lca.be

Website
www.lca.be

Contact persons
Jean-Antoine De Muylder
Seppe De Gelas

Date of establishment
1983

Number of employees
11

Business model
Service provider

Activities in Brussels
Headquarters
Laboratory control

MODULO ARCHITECTS

AGROFOOD - ENVIRONMENT - HEALTHCARE - INDUSTRIAL

CONSULTING ACTIVITIES (TECHNICAL ADVICES) - BUILDINGS

Chemin des Deux Maisons 69/5
B - 1200 Brussels (Belgium)

Phone: +32 2 776 81 00
Fax: +32 2 776 81 09

E-mail
d.holemans@modulo-architects.be

Website
www.modulo-architects.be

Contact person
Didier Holemans

Date of establishment
2000

Number of employees
18

Business model
Service provider

Turnover
1 Mio €

Activities in Brussels
Services

Activities in other countries
Services
EMEA

Corporate description

MODULO architects has an extensive experience in architectural services for pharmaceutical and biotechnological buildings. The type of constructions varies from low-budget spin-off laboratories and incubator buildings to cleanroom production areas and large research facilities. Clients range from university (KULeuven, Ugent, UA, UMH, UCL, ...) and spin-offs (CropDesign, Starlab, Eurobiotec Brussels, ...) to multinational established firms (GlaxoSmithKline, INBEV, Janssen Pharmaceutica, etc).

Market

- Pharmaceutical cleanrooms
- Biotechnological laboratories
- Research Centres
- Interior and exterior architecture
- Permits

State of the technology

- Already on the market

Services description

Architectural services

- Conceptual design
- Building Permit
- Procurement
- Technical detailing
- Site supervision
- Envelope and finishings validation
- Project team collaboration

Innovative aspects

- Creativity of solutions
- Design synergies
- Quality of service and product
- Efficiency
- Communication Comfort
- Energy efficiency
- Sustainable solutions

Type of partnership sought

- Services
- Specialized engineering services
- Clients to share our vision and expertise

Type of partner sought

- Small to medium sized company
- Large company
- Research institute

NAUTADUTILH

AGROFOOD - ENVIRONMENT - HEALTHCARE - INDUSTRIAL

LEGAL ADVICE FROM IP TO REGULATORY AND FROM CONTRACTS TO FINANCIAL - FULL RANGE OF TRANSACTIONAL, ADVISORY AND LITIGATION SERVICES - CONSULTING ACTIVITIES (REGULATORY AFFAIRS, MARKET AFFAIRS)

Corporate description

NautaDutilh is an independent law firm, focused on Belgium, the Netherlands and Luxembourg, offering the full spectrum of legal services to companies active in selected key sectors. NautaDutilh's Dutch roots go back to 1724. The Belgian office was founded in 1994.

Our strategy is not about being the biggest in the market or having the broadest range of services or even having the largest turnover.
It is about doing what we do consistently well: understanding the unique needs and challenges of every key sector and client, thus providing a tailor made legal and client service.
We believe that success in our business will only come through the consistent delivery of quality, value and service to our clients.

Market

Our clients range from start-up ventures to industry leaders, whether in biotech, pharma, medical devices or diagnostics, and also the leading trade associations representing these industries in the Benelux and Europe.What they all have in common is their confidence in the way we work, in our knowledge and experience of their sector and in our ability to provide innovative and practical solutions.

Services description

Life sciences companies have to cope with ever-changing day-to-day economic cycles in a highly regulated marketplace. That's why we build our legal services around the product's and company's life cycle. And we cover every aspect of this from commercial and licensing agreements to financing and mergers & acquisitions, and from patent litigation and marketing authorization procedures to pricing & reimbursement. In other words, we provide a full range of transactional, advisory and litigation services tailored to meet your requirements.

Innovative aspects

We are the only law firm in Belgium with a sector dedicated team that shares business and legal know how on a regular basis and provides the complete range of legal services.

Chaussée de la Hulpe, 120
B - 1000 Brussels (Belgium)

Phone: **+32 2 566 80 00**
Fax: **+32 2 566 80 01**

E-mail
jo.vanwittenbergh@nautadutilh.com

Website
www.lifesciences.nautadutilh.com
www.nautadutilh.com

Contact person
Jo Vanwittenbergh

Date of establishment
1994

Number of employees
135 (70 lawyers)

Number of employees in R&D activities
5

Business model
Service provider

Turnover
+/- 20 Million €

Activities in Brussels
Legal advice, from IP to regulatory and from contracts to financial. We provide a full range of transactional, advisory and litigation services tailored to meet your requirements.

Activities in other countries
Legal advice, from IP to regulatory and from contracts to financial. We provide a full range of transactional, advisory and litigation services tailored to meet your requirements
The Netherlands, Luxembourg, USA, UK

NautaDutilh

OMNICARE CLINICAL RESEARCH

HEALTHCARE

CONTRACT RESEARCH ORGANIZATION - CONSULTING ACTIVITIES (REGULATORY AFFAIRS) - ALL THERAPEUTIC FIELDS

Burgemeester E. Demunterlaan, 1/6
B - 1090 Brussels (Belgium)

Phone: **+32 2 247 94 70**
Fax: **+32 2 247 94 79**

E-mail
leo.huybrechts@omnicarecr.com

Website
www.omnicarer.com

Contact person
Leo Huybrechts

Date of establishment
2000

Number of employees
14

Business model
Service provider

Activities in Brussels
CRO services

Activities in other countries
CRO services

Corporate description

Omnicare Clinical Research NV, established in 2000, is part of the global CRO Omnicare CR Inc.

As CRO we provide support services for pharmaceutical, biotech and devices companies.

We also offer start-up companies consulting services by our experts in Regulatory Affairs, Data management and Biometrics.

Market

CRO services from protocol development to clinical study report writing and this for all phase I to IV studies.

Services description

- Clinical Monitoring
- Project Management
- Data Management
- Biometrics
- Clinical Quality Assurance
- Regulatory Affairs
- Safety
- Clinical Writing and Pharmaceutics

Omnicare Clinical Research

OVIZIO IMAGING SYSTEMS

AGROFOOD - BIOTECH - ENVIRONMENT - HEALTHCARE - INDUSTRIAL

DIAGNOSTIC TOOLS - DEVICE FOR THE BIOPHARMA SECTOR - ENGINEERING SOLUTIONS - TECHNOLOGY PROVIDER

Corporate description

Ovizio is a spin-off company of the "Université Libre de Bruxelles" (ULB) specialized in imaging systems and sensors based on Digital Holographic Microscopy (DHM) created inDecember 2009. The technology is developed around a patent portfolio developed at the Microgravity Research Center of the University, headed by Professor Frank Dubois. The company designs and markets optical instruments and adapted services primarily for the Life Sciences industry. Ovizio has secured funding from its founders, the SRIB (Société Régionale d'Investissement de Bruxelles) and Theodorus II, the spin-off fund of the ULB.

Market

Ovizio's innovative 3D technology generates high quality holographic images with a maximum horizontal resolution of 230nm and a vertical resolution of 2nm, ideal for studying dynamic phenomena in real time. The advanced equipment can be used both in classical microscopy or fluorescence. Typical applications are: bioreactors, biotechnology, thin film applications, blood analysis and laboratory research. Successful industrial trials have demonstrated the high potential and viability of the technology.

Technology description

Digital holography is the technology of acquiring and processing holographic measurement data, typically via a CCD camera or a similar device. Ovizio markets an imaging system based on this patented technology. The product is composed of a microscope device (optical hardware) and advanced software for image capturing, processing and analysis.

Our technical principle, based on improved Digital Holographic Microscopy has the following USP's and advantages:

- Partially coherent light: high quality images in harsh environments for real time analysis of particles in fluids and transparent objects
- Real Time: high acquisition speeds of "microscopic holograms" offer dynamic supervision of industrial processes
- Large depth of focus: observing large volumes bring reliable counting and analyses of particles in fluids out of the narrow focus plane
- Multimodal: fluorescence, bright field (regular imaging), dark field in both transmission and reflection mode in a single device
- Fluorescence: fluorescent holograms without using dyes allow for full analyses of the observed volume
- LED color light: color images based on high power LED's lead to cost effective and robust optical devices

State of the technology

- Available for demonstration

Intellectual Property Rights (IPR)

- Patents granted

Services description

Installation, configuration, customization and maintenance services.

Products description

Ovizio markets 4 versions of its technology:

- oLine: a desktop device for research and lab use
- pLine: a portable device for field research
- iLine: an industrial Holographic device for in-line monitoring
- mLine: an extension unit for classical optical microscopes

Innovative aspects

Ovizio's unique real time high quality 3D imaging technology of microscopic particles allows our customers to obtain detailed data and images of samples. This is far beyond the capabilities of existing technologies, revolutionizing current methods and reducing costs.

Research & Development

2 projects in industrial pre-series stage. Development of specific applications in the biotech area allowing customers to observe bioreactors in real time.

Type of partnership sought

- Distribution agreement
- License agreements

Type of partner sought

- Large company

Rue Engeland, 555
B - 1180 Brussels (Belgium)

Phone: +32 2 600 50 90
Fax: +32 2 600 50 45

E-mail
info@ovizio.com

Website
www.ovizio.com

Contact person
Philip Mathuis

Date of establishment
2009

Number of employees
5

Number of employees in R&D activities
4

Business model
Product & Service provider

Activities in Brussels
Headquarter
R&D: research
Marketing
Distribution

PEPTISYNTHA

HEALTHCARE

PEPTIDE APIs cGMP MANUFACTURING - THERAPEUTICS (SMALL MOLECULES, CHEMICAL MOLECULES, GENERICS/ BIOSIMILARS)

Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)

Phone: **+32 2 264 22 45**
Fax: **+32 2 264 34 70**

E-mail
marc.fouassier@solvay.com

Website
www.peptisyntha.com

Contact person
Marc Fouassier

Date of establishment
1987

Number of employees
40

Business model
Product & Service provider

Activities in Brussels
Headquarter
R&D: research
Manufacturing
Marketing

Activities in other countries
R&D research
Manufacturing
USA

Corporate description

Peptisyntha is a globally recognized GMP manufacturer of clinical and commercial peptides. With peptides dedicated laboratories, kilolabs, pilot and commercial scale manufacturing units (chemical synthesis, HPLC purification and lyophilisation), Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs, therefore supporting its pharmaceutical and biotechnological clients throughout the entire lifecycle of their peptide product.

Peptisyntha's activities are conducted at development and production sites located in Belgium and the USA, the combination of the two offering the choice of solid phase peptide technology, solution phase peptide technology and solid-solution hybrid technology.

Technology description

Peptide manufacturing cost efficiency and continuous improvement are key components of Peptisyntha business model.

As a technology driven company, Peptisyntha has developed a portfolio of innovative technologies and know-hows, particularly applicable to solution phase peptide synthesis: with the objective to shorten synthetic processes/reduce the number of manufacturing steps, control the risks of racemisation, simplify (or even eliminate) HPLC purifications steps, etc.

Besides its long standing experience in the development and production of 'classical' peptides, Peptisyntha also is recognized as an expert in:

- pegylated peptides
- peptides with multiple (up to 4) disulfide bridges
- lipopeptides
- arginine rich peptides
- peptide-protein conjugates

In addition to the peptide production capabilities of its FDA and European authorities inspected sites, Peptisyntha also conducts for its clients a full range of CMC support services: synthesis of impurities and reference standards, development and validation of analytical methods, stability studies, preparation and filing of DMF.

State of the technology

- Already on the market

Services description

- Process development
- cGMP manufacturing
- Quality control
- Regulatory affairs

Products description

Peptides for pharmaceuticals diagnostics and cosmetics.

Innovative aspects

With a dedicated offering in peptide APIs and a history of over 20 years in GMP peptides production Peptisyntha is a manufacturing partner of choice to companies involved in the field of therapeutic peptides.

Type of partnership sought

- Manufacturing/Subcontracting agreement

PFIZER

HEALTHCARE

THERAPEUTICS (CELLS, VACCINES, ANTIBODIES, SMALL & CHEMICAL MOLECULES, GENERICS) - DRUG FORMULATION
DRUG DELIVERY - CELL CULTURE EXPERTISE - DRUG DISCOVERY/SCREENING - MOLECULES SUPPLIER - CARDIOLOGY
CNS – DIABETES – IMMUNE SYSTEM - INFECTIOUS DISEASES – INFLAMMATION – ONCOLOGY – RESPIRATORY DISEASES
GROWTH HORMONES - OPHTALMOLOGY - UROLOGY

Corporate description

Pfizer was founded in 1849 when Charles Pfizer and Charles Erhart decided to open a fine-chemicals business. A modest red-brick building in the Williamsburg section of Brooklyn, New York, serves as office, laboratory, factory, and warehouse.
The company's first product is Santonin - a palatable antiparasitic which is an immediate success. Using deep-tank fermentation, Pfizer is successful in 1944 in its efforts to mass-produce penicillin and becomes the world's largest producer of the "miracle drug." Most of the penicillin that goes ashore with Allied forces on D-Day is made by Pfizer. This is the start of Pfizer's pharmaceutical activities and international expansion.

Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines and global leadership in corporate responsibility. Every day we help 38 million patients, employ more than 100,000 colleagues, utilize the skills of more than 10,000 medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses-adding both years to life, and life to years.

Market

Pharmaceutical market.

State of the technology

- Already on the market
- Available for demonstration
- Development phase

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patent applied - not granted
- Patents granted

Products description

Innovative medicines for humans and animals.

Research & Development

600 R&D projects (133 programs in clinical or registration phase).

In Brussels/country

Phase I & II clinical trials: 1st administration to human volunteers or patients of Pfizer's new medicines in development, in closed setting. (Phase I clinical research unit Anderlecht).

Phase III & IV clinical trials: broad pre- and post registration clinical studies in open settings with Pfizer's new medicines in development and existing products.

Type of partnership sought

- Further research/development support

Type of partner sought

- Research institute
- University

Boulevard de la Plaine, 17
B - 1050 Brussels (Belgium)

Phone: +32 2 554 62 11
Fax: +32 2 554 66 60

E-mail
daniel.vanbellinghen@pfizer.com

Website
www.pfizer.be
www.pfizer.com

Contact person
Daniel Van Bellinghen

Date of establishment
1952

Number of employees
500

Number of employees in R&D activities
+/- 100

Business model
Product & Service provider

Activities in Brussels
R&D: clinical development

Activities in other countries
Headquarter
R&D: research
R&D: pre-clinical development
R&D: drug discovery
R&D: clinical development
Manufacturing
Marketing
Distribution
Discovery, development, production, distribution and commercialization of innovative medicines for humans and animals

PHARCO

HEALTHCARE

NUTRITHERAPY - PHYTOTHERAPY - CHOLESTEROL - STRESS - GLYCEMIA - INTESTINAL FLORA

Rue A. De Witte, 12
B - 1050 Brussels (Belgium)

Phone: **+32 2 648 78 08**
Fax: **+32 2 648 91 38**

E-mail
karima@pharco.be

Website
www.pharco.be

Contact persons
François Motte
Guy Wyvekens

Date of establishment
2003

Number of employees
11

Business model
Product provider

Turnover
3 Million €

Activities in Brussels
Headquarter
Research & Development
Distribution/Sales
Marketing

Activities in other countries
Distribution
Benelux, France, Morocco, Lithuania, Baltic States, Turkey, Spain, Czech Republic, Rumania

Corporate description

Pharco Research was created in 2003. The company is focused on the OTC Market. We are specialized in the nutritherapy and phytotherapy sector. We are active in Benelux, France and Spain.

In Belgium, we have a sale force of 10 people. We are producer and distributor of more then 40 products covering the most important pathologies of the OTC Market. All our products are made in Belgium and France. We are looking to expand our commercial activities into the CEE, Russia an the Maghreb.

Market

Specialized in OTC market.

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- License agreements reached
- Partnership/Other contractual agreement

Products description

- Product to control cholesterol
- Products to manage the symptoms of stress, fatigue, etc
- Products to balance the intestinal flora
- etc

Type of partnership sought

- Export distribution agreement
- Financial resources
- Manufacturing/Subcontracting agreement

Type of partner sought

- Small to medium sized company

PHARCO

SMB LABORATORIES

HEALTHCARE

THERAPEUTICS (CHEMICAL MOLECULES, GENERICS/BIOSIMIILARS) - DRUG FORMULATION - DRUG DELIVERY - CARDIOVASCULAR DISEASES - DIABETES - INFECTIOUS DISEASES - RESPIRATORY DISEASES

Corporate description

Laboratoires SMB SA is a private Belgian familial company involved in the Research and Development, registration and manufacturing of drugs worldwide. More specifically the R&D department of SMB focuses on new drug delivery technologies of pharmaceutical active ingredients which allow a better efficacy/safety profile of the drug, a better patient's compliance, a more cost effective treatment or any other advantage that would improve patient's comfort.

Laboratoires SMB is more specifically specialized in (i) oral formulations like tablets, sustained release pellets, effervescent tablets, semi-solid compositions and (ii) in formulations for inhalation like dry powder inhalers.
Laboratoires SMB also possesses and develops its own new drug called Nacystelyn and currently in development for the treatment of Cystic fibrosis and Chronic obstructive pulmonary disease.

Technology description

- Improved dry powder inhaled compositions
- Oral sustained release pharmaceutical compositions
- Semi-solid compositions of lipophilic drugs with improved bioavailability
- Formulation of effervescent tablets with an innovative low cost manufacturing process
- Others: coated tablets, sprays, enteric compositions, sachets

State of the technology

- Already on the market
- Available for demonstration
- Development phase

Intellectual Property Rights (IPR)

- License agreements reached
- Patents applied - not granted
- Patents granted

Products description

Drug delivery of pharmaceutical active ingredients.

Innovative aspects

- Development of improved dry powder inhaled compositions with higher lung deposition and low airflow dependence
- Development of advantageous oral sustained release pharmaceutical compositions with optimal efficacy/safety ratio and better patient's compliance
- Development of semi-solid compositions of lipophilic drugs with improved bioavailability
- Formulation of effervescent tablets with an innovative low cost manufacturing process
- Co-development: new fixed-dose combination of drugs with therapeutic advantages

Research & Development

+/- 15 projects in clinical stage. New treatment of lung infection in Cystic Fibrosis.

Type of partnership sought

- Distribution agreement
- Further research/development support
- License agreements

Type of partner sought

- Small to medium sized company
- Large company

Rue de la Pastorale, 26/28
B - 1080 Brussels (Belgium)

Phone: +32 2 411 48 28
Fax: +32 2 411 28 28

E-mail
fvdbi@smb.be

Contact persons
Francis Vanderbist
R&D Manager
Frédéric Besaçon
Business Development Manager

Date of establishment
1978

Number of employees
49

Business model
Product provider

Turnover
Approx. 40 Million €

Activities in Brussels
Headquarter
R&D: research
R&D: clinical development
Marketing

Activities in other countries
Manufacturing
Turkey and Porto Rico

STEROP LABORATORIES

HEALTHCARE

GENERICS - DRUG FORMULATION

Avenue de Scheut, 46/50
B - 1070 Brussels (Belgium)

Phone: +32 2 524 39 66
Fax: +32 2 521 60 71

E-mail
info@sterop.be

Website
www.sterop.be

Contact person
Luc Eykerman
CEO, Ind. Pharmacist

Date of establishment
1947

Number of employees
80

Number of employees in R&D activities
6

Turnover
14 Million €

Activities in Brussels
Headquarter
Research & Development
Production
Distribution/Sales

Corporate description

STEROP's is exceptionally well placed in the pharmaceutical sector thanks to its tremendous experience and its management team.

Created in 1947, Sterop presents 60 years of experience in the manufacturing of liquid forms and 25 years in manufacturing of dry forms pharmaceuticals, is an unique asset and irrefutably confirms the quality of the products manufactured by STEROP.

Sterop proposes a large portfolio of products marketed in more than 35 countries.

More than 260 drug formulations are manufactured by STEROP, under:

- Liquid forms: injectable solutions in glass or plastic ampoules, external use solutions, eye and ear drops, ointments, syrups, etc
- Dry forms: powder for external use, tablets, coated or uncoated, pills, etc

The product line is extensive:

- Anaesthetics: lidocaine, procaine, morphine, atropine, methylene blue, caffeine, ephedrine, isoniazide, levorenine, papaverine
- Hormones: progesterone, testosterone
- Minerals: calcium, magnesium, potassium, sodium salts
- Narcotics: morphine, pethidine
- Psychotropics: sodium Phenobarbital, diazepam
- Vitamins: A, B1, B2, B6, B12, C, K, and PP
- Several companies have been taking over by STEROP over the years and helped extending the product range

Technology description

Plastic and glass ampulls for injection, coated tablets, regulatory and registrations.

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- License agreements reached
- Partnership/Other contractual agreement
- Patents applied - not granted
- Patents granted

Products description

Injectables, oral medicines, nutriments, medical devices.

Innovative aspects

260 formulations registered for medicines, medical devices and nutriments.

Research & Development

Anti-age products, health products.

Type of partnership sought

- Further research/development support
- License agreements
- Transfer of know-how
- Manufacturing/Subcontracting agreement
- Joint venture agreement

Type of partner sought

- Small to medium sized company
- University
- Research Institute

SYMFO

HEALTHCARE

CONTRACT RESEARCH ORGANIZATION - DATA MANAGEMENT FOR CLINICAL RESEARCH - TECHNOLOGY PROVIDER - CONSULTING ACTIVITIES (TECHNICAL ADVICES) - ALL THERAPEUTIC FIELDS

Corporate description

Symfo, a privately owned, global ePRO provider, specializes in creating patient-oriented, cost-effective, robust and reliable electronic patient reported outcome (ePRO) and data collection solutions for CROs, pharmaceutical, biotech, medical device companies and academic institutions conducting Phase I to IV clinical studies or postmarketing surveys. Our solutions include a variety of ePRO technologies to suit every client's needs, allowing us to offer everything from "full-service" to "technology transfer".

Market

Patient reported outcomes (PROs) are data obtained directly from patient self-reports, and their use in clinical trials is increasingly important. This is reinforced by the recent FDA publication of the PRO Guidance. Very often in clinical trials, primary efficacy endpoints relate to patient data.

Symfo is specializing in the collection of patient reported outcomes in clinical trials, Phase I to IV and beyond. Our customers are Pharma companies, Biotech companies, CROs, Academies and Medical device companies. 50% of our customers are located in the US and 40% in Europe and 10% in the rest of the world.

Symfo has headquarters in Brussels, Belgium and in Boston, MA.

Symfo has proven experience in emerging markets in addition to the US and Europe. We have delivered more success in Brazil, China, Israël, Russia, as well as out of the way places like Vietnam, Indonesia, Malaysia or Thailand, than any other. This is only possible using Symfo's multiple data transmission technologies deployed on a single device. Concerns about country/region specific modem compatibility and cell phone/internet coverage simply become irrelevant with Symfo.

Technology description

The following describes the patient data collection process involved for each handheld e-Diary:

- Symfo/CRO/Project manager develops the application that is installed on the hardware (Leonardo, Michelangelo). This hardware (called Michelangelo and Leonardo) is handed over to the patient who collects data as specified in the protocol
- All data recorded by the patient are automatically stored in an encrypted mode (128-bit encryption) on the Secure Digital (SD) memory card (Michelangelo) or in a permanent memory (Leonardo)
- Data transmitted by the patients arrive on Symfo's/customer's servers in an encrypted mode. Data are decrypted and decoded and immediately sent to a repository for viewing and reporting purposes. This reporting tool can be the customer's EDC tool or Symfo's repository tool
- Patient data can be accessed via Symfo's repository on www.symfo.org
- Data are also pushed in real time or at regular and/or pre-defined intervals to a third party server using various formats including ASCII and XML to accommodate the third party database structure. Data can be integrated into any EDC, CTM or IVR system (such as Rave, Expert, InForm, etc)

Innovative aspects

Symfo is proud to be the pioneer in developing a simple yet powerful e-Diary design tool which simplifies the process of creating your electronic patient diary solutions. ARTIST puts customers in control of their patient data collection process!

Artist allows designing the questionnaires, formatting the screen layouts, creating edit checks, and deploying an ePRO solution to numerous Windows Mobile based devices.

Research & Development

- First project (ARTIST): Improvement phase
- Second project (repository): specification IT projects
- Third project: development of a lowcost hardware

Type of partnership sought

- Distribution agreement
- Further research/development support
- Joint venture agreement
- License agreements
- Transfer of know-how

Type of partner sought

- Small to medium sized company

Avenue Winston Churchill, 239
B - 1180 Brussels (Belgium)

Phone: +32 2 340 82 28
Fax: +32 2 340 82 29

E-mail
serge.bodart@symfo.com

Website
www.symfo.com

Contact person
Serge Bodart

Date of establishment
2000

Number of employees
7

Number of employees in R&D activities
2

Business model
Service provider

Activities in Brussels
Headquarter

Activities in other countries
R&D research
Marketing
Distribution
Luxemburg, USA, Australia

THERABEL PHARMA sa/nv

HEALTHCARE

DRUG FORMULATION - DRUG DELIVERY - CARDIOVASCULAR DISEASES - ONCOLOGY - ANTIBIOTICS - NSAI - CARDIOLOGY

Rue Egide Van Ophem, 108
B - 1180 Brussels (Belgium)

Phone: **+32 2 370 46 11**
Fax: **+32 2 370 46 90**

E-mail
generalities@pharma.therabel.com

Website
www.therabel.com

Contact person
Gabriël Verhelle
General Manager

Date of establishment
1945

Number of employees
80

Business model
Product & Service provider

Turnover
54 Million €

Activities in Brussels
Headquarter
R&D: clinical development
Marketing
Promotion of pharmaceutical products

Activities in other countries
Headquarter
R&D: clinical development
Manufacturing
Marketing
France: Promotion and manufacturing of pharmaceutical products
The Netherlands, Italy and UK: Promotion of pharmaceutical products

Corporate description

The Therabel Group, a privately owned pharmaceutical laboratory, sets itself apart from the highly diversified pharmaceutical industry through the quality of the men and women it employs, the way they work in close cooperation and the desire they share to move forward both in taking charge of their own futures and in helping build Therabel's future.

Therabel promotes a spirit of enterprise, volutarism and enthusiasm through its "human" dimenson.

Every one of us at Therabel works in an environment in which valuable people are allowed to give the best of themselves to the company.

The company's only goal is to focus all of its strenghts and talents on its know-how to be at the service of the medical field of patients by providing innovative prescription drugs. Therabel is not guided by quarterly and stock market results. It focuses on five-year projects and on long-term objectives. This has enabled the company to position itself for the long run since 1945 leading it to strong and to a threefold increase in turnover in 10 Years.

After 60 years in business, first in Belgium then in France, the Netherlands and Italy, Therabel intends to become a European pharmaceutical group. It will extend its presence to all major European Community countries while maintaining the human scale of its organization, its spirit, ethics and freedom of action.

State of the technology

- Already on the market

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patents granted

Innovative aspects

In addition to its talent-based culture, other facets of Therabel separate it from the pharmaceutical industry majors:
Therabel does no basic research. It invests in phase 3 clinical studies of new molecules created by trusted partners and in the development of new indications and galenic formulations of existing molecules.
Therabel does not rely on an array of production centres specialized in a variety of chemical and pharmaceutical forms. It has a single, modern plant flexible enough to produce different types of dry pharmaceutical products. Therabel also works with contractors.

Type of partnership sought

- Further research/development support
- Joint venture agreement
- License agreements

Type of partner sought

- Small to medium sized company
- Large company
- University

TRENKER LABORATORIES

HEALTHCARE

HUMAN USE DRUGS - FOOD SUPPLEMENTS - NUTRIENT

State of the technology
- Already on the market

Intellectual Property Rights (IPR)
- Exclusive rights
- Licence agreements reached
- Partnership/Other contractual agreement
- Patents granted

Research & Development
2 projects. Molecules in development.

Type of partnership sought
- License agreements

Type of partner sought
- Small to medium sized company
- Large company

Corporate description
Trenker Laboratories S.A. was founded in 1933 by Rodolphe Henri Trenker. We have been independent ever since and this has helped us remain very responsive. Our high performance equipment and highly qualified staff have enabled us to offer a wide range of innovative and effective drugs and nutritional supplements. Our Production and Quality Control departments meet the strictest European Standards (GMP and GLP) and are, certified by the Belgian Ministry for Public Health.

Our Research & Development department works closely with the best universities in the country, leading to the development of new, ever-improving entities for increased patient satisfaction.

Although our nutritional supplements are not drugs, they are produced and controlled according to pharmaceutical standards. This provides a guarantee for patients regarding the quality and purity of the ingredients used, their analysis and traceability, and ensures that principles of "good practices" applied in the pharmaceutical industry are strictly adhered to during the production process.

Avenue Dolez, 480/482
B - 1180 Brussels (Belgium)

Phone: +32 2 347 02 53
Fax: +32 2 374 68 81

E-mail
info@trenker.be

Website
www.trenker.be

Contact person
Rodolphe Trenker

Date of establishment
1933

Number of employees
38

Number of employees in R&D activities
5

Business model
Product provider

Activities in Brussels
Headquarter
Production
Distribution/Sales

TRENKER

UCB

HEALTHCARE

THERAPEUTICS (ANTIBODIES, CHEMICAL MOLECULES) - CNS - IMMUNOLOGY

Allée de la Recherche, 60
B - 1070 Brussels (Belgium)

Phone: +32 2 559 99 99
Fax: +32 2 559 99 00

E-mail
contactucb@ucb.com

Website
www.ucb.com

Contact person
Didier Malherbe

Date of establishment
1928

Number of employees
400

Number of employees in R&D activities
25

Business model
Product provider

Turnover
3,1 Billion €

Activities in Brussels
Headquarter
Marketing

Activities in other countries
R&D: research
R&D: pre-clinical development
R&D: drug discovery
R&D: clinical development
Manufacturing
Marketing
Distribution.
Employing more than 9,000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Corporate description

UCB, Brussels, Belgium (www.ucb.com), established in 1928, is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders.
Employing more than 9,000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

State of the technology

- Already on the market
- Development phase

Intellectual Property Rights (IPR)

- Exclusive rights
- License agreements reached
- Partnership/Other contractual agreement
- Patents applied - not granted
- Patents granted

Products description

Main products are for the treatment of epilepsy, Parkinson disease, Crohn's disease, Rheumatoid arthritis, Systemic Lupus Erythematosus.

Research & Development

Investment in R&D (2009: €674 million).

A world leader in antibody research:

- SLAM technology to rapidly isolate functionally active antibodies
- Biological scaffolds to create more tolerable antibody-based therapies
- Pegylation to enhance the specificity and cost efficiency of biologics
- Unique and patented expertise in targeting the SV2A protein
- A large library of proprietary chemicals to unravel the role of SV2A in epilepsy and other diseases

2 Research Centres of Excellence:

- Braine-l'Alleud (Belgium) covering CNS disorders
- Slough (UK) covering oncology/immunology

Over thirty major R&D partnerships: includes Amgen (anti-sclerostin for bone loss disorders) .

An intellectual property estate of a large number of patent families.

Type of partnership sought

- License agreements

Type of partner sought

- Small to medium sized company
- Large company
- Research institute
- University

UNIBIOSCREEN

HEALTHCARE

THERAPEUTICS (SMALL MOLECULES) - ONCOLOGY

Corporate description

Unibioscreen is a Brussels based private specialist oncology company. Focus is on innovative "first in class" oncology therapeutics, mainly sourced from plants. Unibioscreen is founded in May 1999. Since incorporation, Unibioscreen raised almost 30 million euros. Unibioscreen's investors are ING, Société Générale Biotechnology Fund, SRIB, Technowal, E-Capital, Hunza Ventures, UFG-group, business angels and founders. Unibioscreen also received grants from the Brussels Region.

Market

Cancer patients: cancer represents one of the most attractive therapeutic areas; it represents a high value market with tremendous growth potential. The worldwide oncology market is predicted to continue growing faster and to become the number one therapeutic class in revenue terms.

Technology description

Unibioscreen used natural products (plants and marine sponges) as the major source for the identification of novel hits and leads.
Unibioscreen pursued an efficacy-based anticancer drug discovery to discover and to patent new chemical entities. Innovative chemistry around natural compound leads. Selection of promising drug candidates based on: activity in robust models of incurable human cancers, low toxicity, ability ideally to overcome apoptosis resistance & multi drug resistance phenomena, manufacturing expected in high yield and cost-effectiveness

Intellectual Property Rights (IPR)

- Exclusive rights
- Patents applied - not granted
- Patents granted

Products description

Unibioscreen has successfully discovered, patented and developed two drug candidates now in clinical Phase I trials in cancer patients.

UNBS1450 is hemi-synthesized from a novel cardenolide: 2''-Oxovoruscharin, extracted from Calotropis procera root bark.
UNBS1450 has a unique MoA: UNBS1450 is a sodium pump antagonist (targeting cancers that over-express the sodium pump alpha subunits). Preclinical work has shown that UNBS1450 provokes disorganization of the actin cytoskeleton and kills cancer cells through non-apoptotic cell death mechanisms (i.e. autophagy) and that UNBS1450 overcomes major pathways responsible for the failure of existing cancer chemotherapy (multi drug resistance). A phase I study is ongoing; patient enrollment started in Q4 2008. Goal of the study is to determine the dose limiting toxicities (DLT) & maximum tolerated dose (MTD), to determine pharmacokinetics and pharmacodynamic endpoints, and to look for early evidence of antitumor activity. No DLTs and no drug related SAEs/SUSARs have been observed so far.

UNBS5162 is a novel naphthalimide, with a unique MoA, discovered, patented & developed by Unibioscreen. UNBS5162 has in vitro efficacy in a wide range of tumor cell lines & antitumor activity in several in vivo models. Also shown activity as a radiosensitizer agent in vitro. Phase I trial in cancer patients has been performed in the USA under an IND. 24 patients have been treated in 8 dose cohorts. The study has recently been closed to analyze clinical results, alternative schedules and further development steps.

Innovative aspects

Focus on novel, first-in-class oncology therapeutics. Unibioscreen built its competitive edge on exploiting through hemi-synthesis the structure activity relationship (SAR) of natural product chemistry and through development and use of unique technologies & demanding orthotopic models of cancer.

Research & Development

3 projects in discovery phase and clinical development phase: UNBS1450, UNBS5162, Hellebrin project. The objective of the Hellebrin project is to design a novel compound binding to/targeting the sodium pump, but belonging to a different chemical class than UNBS1450. The program is composed of UNBS5416-related compounds UNBS5416-derivatives are novel bufadienolides, hemi-synthesized from hellebrin & hellibrigenin, isolated from Helleborus purpurascens. The compounds are potent inhibitors of the sodium pump and anti-proliferative to a range of cancer cell lines (nM activity).The compounds have the potential for an enhanced therapeutic margin, given their lower toxicity in vivo to rodents.

Type of partnership sought

- Financial resources
- Further research/development support
- Joint venture agreement

Type of partner sought

- Small to medium sized company
- Large company
- Research institute

Joseph Wybranlaan, 40
B - 1070 Brussels (Belgium)

Phone: +32 2 529 58 56
Fax: +32 2 529 59 42

E-mail
christiane.verhaegen@unibioscreen.com

Website
www.unibioscreen.com

Contact person
Christiane Verhaegen

Date of establishment
1999

Number of employees
3

Number of employees in R&D activities
2

Business model
Product provider

Activities in Brussels
R&D: pre-clinical development
R&D: clinical development

Unibioscreen s.a.

INCUBATORS

BLSI (BRUSSELS LIFE SCIENCE INCUBATOR)

Clos Chapelle-aux-Champs, 30 bte 3004
B - 1200 Brussels (Belgium)

Phone: +32 10 39 00 27
Mobile: +32 497 16 25 53

E-mail
b.buntinx@sopartec.com

Website
www.blsincubator.be

Contact person
Benoît Buntinx

Brussels Life Science Incubator (BLSI) is the new biosciences incubator of the Brussels-Capital Region. BLSI offers a dynamic and stimulating environment for entrepreneurs and young innovative companies developing their activities in the biotech, medical devices and e-health sectors.

Our offer

High quality furnished offices and fully flexible laboratories

BLSI offers a 2.350 m² gross area distributed in 30 office/lab modules established on 2 floors and connected with a modern and convivial lounge area. Furthermore, common areas, as well-equipped meeting rooms, cafeteria with catering services, copying and scanning facilities are shared within the BLSI entrepreneurial community.

Proximity to an extensive knowledge base

BLSI is at the heart of the Brussels campus of the Université catholique de Louvain and is surrounded by the faculty of medicine and its research institutes like the de Duve Institute (5,500 students and 1,000 teachers / researchers), the Cliniques Universitaires Saint-Luc (900 beds and 4,700 employees) various high schools (7,000 students) and famous research centers such as the European Organization for Research and Treatment of Cancer (EORTC - 200 employees). BLSI proximity allows hosted companies to rely on a pool of highly-skilled human resources and to benefit from a wide range of services offered by the UCL laboratories such as a privileged access to scientific equipment.

Business support and mentoring

BLSI provides young entrepreneurs and start-up companies with professional business support such as:

- access to a specialist business support network
- business information and networking events
- assistance with grants and fundraising
- assistance in recruitment (operational & board level)

Location

BLSI is situated on the UCL campus in Brussels, at the heart of Europe and close to the European institutions. BLSI is ideally connected to the main highways reaching Brussels with a bus station and a subway station at the door and is only a 5-minutes-drive away from Brussels National Airport.

Partners

BLSI main shareholders are the Brussels-Capital Region and the Université catholique de Louvain (UCL), a major Belgian university, with more than 21000 students and 5000 academics, researchers and staff. UCL has a long tradition of technological companies' creation in the health sector, with famous success-stories as IBA, IBt or Telemis.

BLSI is managed by the Louvain Technology Transfer Office, composed of a multidisciplinary team combining a strong scientific background and an accomplished business experience, supported by an extended network of legal, financial and commercial experts.

Brussels Life Science Incubator will open its doors mid-2011 after a full renovation of the hosting facilities.

EEBIC (ERASMUS EUROPEAN BUSINESS & INNOVATION CENTER)

"Erasmus European Business & Innovation Center"(EEBIC), the Brussels-Capital Region business and innovation centre was created in 1992. It has a comprehensive administrative infrastructure which enables you to start up your business under the best possible conditions.

EEBIC has very strong connections with academic partners who call upon its expertise in order to create spin-offs.

The ULB has a 30% stake in the SA EEBIC and is thus positioned as a privileged and active shareholder.

The 6.600 m^2 building which houses start-ups and where the EEBIC manages its activities is also the university's property.

Academic research resulting from the ULB's laboratories can be developed through the creation of university spin-offs. EEBIC owes its reputation in this field to the number of spin-offs thus created and the successful managerial orientation of the spin-offs conducted by its team and network of experts.

The EEBIC team is assisted by legal, scientific and management experts, in order to assess and support pioneering projects, which require specific skills.

Our scientific experts unsparingly offer their precious advice on emerging technologies:
- Biotechnology
- Chemical engineering
- Micro-electronics
- Positioning, management consultancy, patenting, etc

EEBIC provides you with a whole range of resources so that your project has the greatest possible chances of success. Apart from the preparation of a "business plan", EEBIC offers assistance with regard to strategic positioning, day-to-day management, intellectual property protection, etc.

Spin-offs created through the EEBIC
- Henogen
- Euroscreen
- Euro Heat Pipes
- Ovizio
- Bone Therapeutics

Avenue Joseph Wybran, 40
B - 1070 Brussels (Belgium)

Phone: **+32 2 529 58 11**
Fax: **+32 2 529 59 11**

E-mail
jvn@eebic.be

Website
www.eebic.be

Contact person
Jean Van Nuwenborg

EEBIC
FROM IDEA TO COMPANY

EUROBIOTEC

Allée de la Recherche 4
Zoning Industriel Erasmus
B - 1070 Brussels (Belgium)

Phone: **+32 2 526 02 80**
Mobile: **+32 473 71 68 44**
Fax: **+32 2 527 94 14**

E-mail
jp.simon@eurobiotec.be

Website
www.eurobiotec.be

Contact person
Jean-Paul Simon

Biotechnology Innovation and Incubation Centre (Eurobiotec) which is involved in the emergence of new industrial activities in the white and red biotechnology.

The Centre is ideally located in the Erasmus Industrial Zone in Brussels, in infrastructures that extend across almost 4000 m². The Centre is set up close to the Medical Faculty of the Université Libre de Bruxelles (ULB) and the "Centre d'Enseignement et de Recherche des Industries Alimentaires" (CERIA), which will encourage collaboration with these academic partners as well as other Brussels, Belgian and European players.
The management team has a 25 years old expertise in the practice of industrial biotechnological partnerships as well in Belgium, in EU and in the States.

The Centre's activities are structured into two divisions:
Process Development Division
The Process Development Division offers a biotechnological platform presenting 4 independent fermentation lines, two purification lines and a dry formulation line.
The Centre belongs as a Contract Development Organization characterised by a quality offering, supported by efficient tools allowing the followups of:

- Four L2 and LS2 fermentation lines of 2, 10, 15 and 750 litres
- Two independent suites of laboratories equipped with facilities for protein purification
- And two independent rooms for lyophylisation

The scientific team has a 25 years old expertise in the fields of propagation of natural or genetically modified micro-organisms (bacteria and yeasts up to hazard class 2), purification of proteins for medical or technological uses and the formulation of living biological starters.

Incubation Division
The Incubation Division will house 4 to 5 spin-offs from the sector in a "plug-and-play" environment.

The Centre is a technological bioincubator offering:

- Pre-equipped premises to spin-offs and start-ups with high quality accommodation for spin-offs in the form of 12 modules of 75 m² including pre-equipped laboratories and offices. Spin-offs are allowed to supplement this basic equipment as they wish
- Provision of meeting rooms, a personalised reception and an equipped canteen
- Technological and scientific coaching provided by a "Scientific Board" consisting of the team of resident experts and external members which analyses the projects, supervises the accommodation of spin-offs, advises them on their technological and strategic choices, coaches them in their activities and guides them within the Process Development Division
- A financial support to the management consultancy is offered to the spin-offs accommodated in the "Incubation Division" by the distribution of grants that enable them to choose an external consultant to provide management consultancy

The Centre enables its customers to scale-up processes to products samples intended for industrial feasibility studies (implementation of enzymes, toxicology analyses, devising formulations), ensuring that the customer maximises the added value of its project.

The Centre documents for its customers the developments carried out at their request, in the form of a specification of the process directly applicable in GLP or GMP production. A multidisciplinary team covering the technological implementation, analytical follow-up and quality control will write this.

The Centre is characterised by an innovation strategy in the sectors of fermentation, unit operations downstream for purification of proteins or the production of biological starters to improve the service offering to customers.

The centre does and will participate in R&D programmes supported by the European Commission and by Belgian regional bodies.

SOLVAY RESEARCH AND TECHNOLOGY CENTRE

Welcome to the Innovation World

Solvay Research and Technology Centre is opened to start-ups.

The initiative by Solvay Research and Technology fits perfectly with the objectives of the European Commission and of the Brussels-Capital Region by encouraging R&D within small-sized creative promising and ambitious companies which if their project succeed can become the real drivers of new industrial activities.

In order to enable the start ups to match their ambition and devote themselves to their core competences, Solvay Research and Technology is offering the access to technology ressources. The selected companies receive research premises and back-up support and particular favorable rental conditions for a two year period.

The initiative is unique: a large research centre of a world size group, a leader in its spheres of activity is supporting and encouraging research in chemistry, materials, plastics on the frontiers of existing activites in which the start up retains full autonomy and full ownership rights to its research.

Solvay Research and Technology is located ideally to the north east of Brussels, close to the ring, within an easy distance from the International Airport in a 22 hectares parc with 120.000 m² of labs, offices and workshops, where the young entrepreneurs have the opportunity to meet 600 scientists, engineers, technologists of Solvay .

Solvay Research and Technology offers:

- Analytical services with up-to-date know-how and equipment for qualitative and quantitative analysis
- A "process engineering" department specialized in the design and technical-economic assessment of pilot and industrial production facilities
- Specialists in process automation, process control and information technology
- A large team of experts who can assess the properties of plastics and materials, corrosion issues and finished objects, and advise on potential applications
- A documentation department with access to worldwide databases plus a wellstocked scientific library
- The advise from the Intellectual Property experts
- Technical building management services with assembly teams, electricians, IT experts, security and hygiene advisers, all vital for the site to operate smoothly
- A modern visitor infrastructure with fully-equipped meeting and videoconference rooms, guarded parking areas, etc
- Ancillary services including a company restaurant, sandwich bar, fitness rooms and crèche to enhance the quality of life and user- friendliness of the site and facilitate the researcher's work

Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)

Phone: **+32 2 264 29 83**
Fax: **+32 2 264 34 20**

E-mail
innovation.world@solvay.com

Website
www.solvay.com/innovation/appliedinnovation/

Contact person
Thierry Cartage

SOLVAY

SUPPORT
ORGANIZATIONS

Bio&Pharma in Brussels

BEA (THE BRUSSELS ENTERPRISE AGENCY)

Tour & Taxis
Avenue du Port, 86c b211
B - 1000 Brussels (Belgium)

Phone: **+32 2 422 00 24**
Fax: **+32 2 422 00 43**

E-mail
pla@bea.irisnet.be

Website
www.bea.irisnet.be

Contact person
Pierre Lamy

At the **"Brussels Enterprise Agency"(BEA)**, the Brussels SME's, start-ups, self-employed persons, as well as foreign investors will find the answers to all their questions concerning the creation or development of an economic or innovative activity in the Brussels-Capital Region.
The "BEA" is structured around four departments, offering a panoply of very concrete services:

Technology & Innovative Projects

Informs, advises and supports you for all your innovation projects (financing sources, strategic information, partners, etc).
Within this department, 6 areas of activity are the focus of particular attention:
"Ecobuild", "Environmental Technologies", "Food Processing", "Healthcare", "New Information and Communication Technologies (NICT)" and "Urban Industries".

The "Health Business Unit" assists companies and provides the following services:

- Identification of technology needs
- Technological validation of projects
- Market validation of projects
- Analysis of business plans
- Search for financing sources and available public aid
- Promotion of intercompany partnerships and alliances
- Search for strategic information (market, competitors, intellectual property rights, etc)
- Guidance and assistance to sources of technological expertise (research centers, universities, etc)
- Organization of technology & business partnering events for the medical device and biotech sectors

The "Health Business Unit" also develops also a cluster stategy to support, through specific services and actions, two Brussels Life Science clusters: the "Diagnostic & Telemedicine" and the "Bio&Pharma".

The description of the different actors of both clusters are described in specific catalogs: "Diagnostic & Telemedicine in Brussels" and "Bio&Pharma in Brussels" and on a specific website: www.biopharmainbrussels.com, where you can also subscribe to our newsletter.

The **"Health Business Unit"** supports internationalization of the companies and organizes common stands for the Brussels companies on main medical fairs (Bio US, MEDICA, etc) and inter-clusters missions.

International Relations Department

Identifies and attracts foreign investors who wish to or might be persuaded to set up shop in the Brussels- Capital Region (www.investin-brussels.com). To inform you, find project partners and help you take part in funded European R&D projects for health sectors. It also keeps you informed about and provides access to European programmes for R&D and innovation (European financing, identification of European technology partners, export/import of technologies).

Economy & Starters

Provides you with economic, legal, statistical and regulatory information useful for the creation or expansion of an activity in the Brussels-Capital Region.

Town Planning & Environment

Provides concrete responses on the many urban planning and environmental regulations and procedures (permits, public aid available, technologies, etc).

THE BRUSSELS ENTERPRISE AGENCY

BIO.BE

The "Belgian Association for the Biotechnology Industry" (Bio.be) was founded in January 2006 and is now an integrate in essenscia, the Belgian chemical and life sciences federation.

Bio.be represents companies and professionals involved in research, development, testing, production or marketing of biotechnology applications, as well as those servicing the biotechnology community.

BIO.BE ACTIVITIES

The association stimulates, promotes and defends biotechnological innovation and entrepreneurship as an essential factor of economic growth, of more and better employment and of an expanded science and skills base.

In the Belgian federal state Bio.be represents the interests of the biotechnology industry by anticipating, shaping, steering and correcting our regulatory environment and by interacting or allying with other stakeholders such as patient groups and other intermediate or final users, media, policymakers or fund providers. In addition, Bio.be represents its members towards relevant trade, industry, business or academic organizations in Belgium, Europe and worldwide.

Bio.be's members are offered support for raising their standards, by finding or creating the tools, introductions and networks required for reaching their full potential.

Bio.be pays particular importance to the specific needs of our entrepreneurial members, whose success will determine the future of biotechnology in Belgium.

Diamant Building
Boulevard A. Reyers, 80
B - 1030 Brussels (Belgium)

Phone: **+32 2 238 98 47**
Fax: **+32 2 231 13 01**

E-mail
cb@essenscia.be

Website
www.bio.be

Contact persons
Johan Vanhemelrijck
Manager

Nathalie Poissonnier
Secretary General

Bio.be

BRUSSELS EXPORT

Avenue Louise, 500 b4
B - 1050 Brussels (Belgium)

Phone: **+32 2 800 40 00**
Fax: **+32 2 800 40 01**

E-mail
infos@brussels-export.irisnet.be

Website
www.brusselstrade.be

Contact person
Isabelle Laverge

E-mail ilaverge@mrbc.irisnet.be
Phone +32 2 800 40 85

"Brussels Export" is a partnership between two organizations: the Foreign Trade Department of the Brussels-Capital Region, which is a government office, and Brussels Entreprises Commerce and Industry (BECI), which is privately managed. This partnership involves close collaboration between these two organisations, whose offices are situated under one roof at 500 Avenue Louise, Brussels. Their common objective is to promote foreign trade and assist Brussels companies, by offering a comprehensive range of services:

- Personalised assistance to exporters, in Brussels and abroad, thanks to a worldwide network of 88 Economic and Commercial Attachés
- Financial incentives for small and medium sized companies helping them pay business trips, take part in international trade fairs, elaborate export promotion materials, appeal to foreign trade consultants, send their staff on foreign trade training courses, create representative offices abroad, etc
- Collective promotional activities such as the organization of trade missions and commercial contact events abroad, invitation of foreign buyers to Brussels and participation of groups of Brussels based companies at international exhibitions and trade fairs
- Tailored advice from our commercial prospectors, who are visiting companies, in order to obtain a better understanding of their activities and needs
- Distribution of information on foreign markets, administrative export procedures and business opportunities, through our website, various other publications and business information meetings

EEB (ENTERPRISE EUROPE BRUSSELS)

Helping small businesses with the challenges that go beyond their familiar context: that is what the European Commission offers with the **"Enterprise Europe Network" (EEN)**.

Young and very small companies often do not have the means or the time to stay informed about the different European support programmes. Neither can they fully exploit the new technological and commercial opportunities, especially outside their usual scope of action and local markets.

The "Enterprise Europe Network" wants to close precisely this gap. Building on an experience of more than 15 years, this network has been launched by the European Commission in 2008 as the one-stop shop where entrepreneurs can get information, advice and a vast array of personalized supporting services.

With its 500 local contact points and 4000+ experienced staff active in more than 40 countries (EU 27 + Armenia, Bosnia and Herzegovina, Chile, China, Croatia, Egypt, Iceland, Israel, Montenegro, Norway, Russia, Serbia, Switzerland, Syria, the former Yugoslav Republic of Macedonia, Turkey, USA), this is simply the biggest International service network for companies.

Even though it is open to companies and institutions of varying size and activities, the network is mainly focused on SMEs. Thanks to the network, entrepreneurs have the opportunity to:

- Promote, acquire and use innovation in the company
- Become faster and more efficiently active on an international level.
- Get information and advice on European policy, law and norms
- Find quality partners across borders for commercial, innovation or research projects
- Get access to European projects and financing

These services are free of charge and are based on the "no wrong door" principle: a client may access the network through any network contact point, (s)he will then be either personally assisted or introduced to the relevant network partner.

In Brussels, the network is represented by "**Enterprise Europe Brussels" (EEB)**, a collaboration between the Brussels Enterprise Agency (BEA) and Brussels Enterprises Commerce and Industry (BECI).

Enterprise Europe Brussels helps companies and researchers of all sectors of industry and research, including the Life Science sector.

Tour & Taxis
Avenue du Port, 86c b211
B - 1000 Brussels (Belgium)

Phone: **+32 2 422 00 21**
Fax: **+32 2 422 00 43**

E-mail
nbe@bea.irisnet.be

Website
www.bea.irisnet.be

Contact person
Nadine Bettens

enterprise europe network
Business Support on Your Doorstep

INDUTEC

Avenue Nellie Melba, 73
B - 1070 Brussels (Belgium)

Phone: **+32 2 534 33 79**
Fax: **+32 2 434 33 95**

E-mail
info@indutec.be

Website
www.indutec.be

Contact person
Stéphane Wojcik

"InduTec" has been created on the initiative of the 4 Brussels Industrial Engineering Institutes to provide a common and complementary technology transfer office (interface) to Brussels businesses.

The four Institutes represented are:
ECAM – Haute Ecole Leonardo da Vinci
Master's Degrees in: Automation, Civil construction, Electromechanics, Electronics, Surveying Sciences and, ICT.

EHB (Erasmushogeschool Brussel) – Industrial Sciences & Technology
Master's Degrees in: Electromechanics (Aeronautics, Transport Technologies and, Mechanical Design), Industrial Technologies – Electronics and Information Technology (Embedded Systems, Information Technology) and, Industrial Technologies – Urbanism and Spatial Planning.

IM (Institut Meurice Chemistry Biochemistry) Haute Ecole Lucia de Brouckère
Master's Degrees in: Chemistry (Analytical Chemistry and Environmental Engineering, High Polymers & Coatings), Biochemistry (Biochemical & Brewery Engineering, Food Technologies) and Pharmaceutical Biotechnologies.

ISIB (Institut Supérieur Industriel de Bruxelles) Haute Ecole Paul-Henri Spaak
Master's Degrees in: Chemistry, Electronics, Electrical Engineering, ICT, Mechanical Engineering (Aeronautic and Electromechanics) and Physics and Nuclear Engineering.

Through InduTec, more than 200 professors and researchers put their scientific know-how at the companies' service, drawing as well on various research centres or associated organizations/bodies.
Acting as an external R&D centre for Businesses and Entrepreneurs, InduTec works in both directions:

- Finding industrial/business partners for technological innovations initiated in one of the Institutes when it becomes necessary
- Responding to any requests for research and/or consulting work from the industrial world through contractual research, industrial sub-contracting, collaborative Research and embedded labs

In addition to Biotechnological sciences, the Institutes offer the following area of expertise available to research program and consulting services: Agro-food technologies, Electronics and ICT, Electromedical equipments, Industrial and Material technologies, Medicine & Human health, Physical sciences & Measurements, Protecting man and Environment, Rational use of energy, and Transport technologies.

InduTec welcomes all collaboration, from the private inventor to the long standing companies, and acts in:

- Engineering processes
- Technological assessment
- Economical assessment
- IPR support
- R&D funding evaluation
- Technical prototype building
- Commercial prototype development
- Marketing plan
- Business plan

At InduTec, we match our engineers' potential and know-how with Industry's needs. This makes us the ideal working partner as far as developing projects that cover various fields of application (at regional, federal or European level) are concerned.

With regard to our partners (public and private), projects always occur in a "win-win" context since both sides of the collaboration aim at mutual satisfaction.

ISRIB (INSTITUTE FOR THE ENCOURAGEMENT OF SCIENTIFIC RESEARCH AND INNOVATION OF BRUSSELS)

The Institute for the encouragement of Scientific Research and Innovation of Brussels (ISRIB) is a funding organization that encourages, promotes and supports scientific research and technological innovation at companies, universities and higher education institutes located in the Brussels-Capital Region.
The main goal of the Institute consists in increasing the economic activity of the Region and in developing local excellence.

ISRIB actions in favour of SMEs and large companies

ISRIB launches one to two call(s) for proposals a year. In this framework, ISRIB grants subsidies and repayable loans to support industrial research or experimental development projects. To benefit from this action, companies have to submit a proposal in which they present their project. This proposal is reviewed by experts (ISRIB scientific advisers and/or academic experts). Their reviews serve as basis for the funding decision.

Additional actions dedicated to SMEs

Beyond the R&D-funding, SMEs can benefit from regional funds if they want to delegate the carrying out of a feasibility study to a university, a higher education institute or a research centre.
The aim of this action is to enable SMEs to evaluate the industrial potential of an innovation before starting a more ambitious research or development program.
Finally, SMEs can benefit from regional funds for the deposition and enforcement of patent(s), upon condition that the related invention(s) originate(s) from projects funded by the Region.

ISRIB actions in favor of universities and higher education institutes

In the framework of the "impulse" action, ISRIB funds cooperative research programs with a midterm economic goal. The research consortia are composed of teams of highest standard belonging to the universities, institutions of higher education and/or collective research centres located in the Brussels-Capital Region.

Three actions are currently in progress:
- the "impulse program" Environment
- the "impulse program" ICT
- the "impulse program" Life-Sciences

ISRIB actions in favor of researchers

The annual action "Spin-Off in Brussels" supports researchers who aim at creating a business out of the results of their research activities. This action consists in funding the development project as well as the economic education (i.e. Master in Business development) of the researcher.

With "Prospective Research for Brussels", IRSIB supports Ph.D. students and graduate researchers, whose work contributes to the development of the Brussels-Capital Region. The topics for eligible projects are defined every year in collaboration with the public authorities of the Brussels-Capital-Region.

Finally, with "Brains back to Brussels", ISRIB encourages high-level scientists from other regions or countries to engage in science and research in the Brussels-Capital Region.

Competence Centres

The support of competence centres aims at reinforcing the excellence of the Region.
- SIRRIS: Research, consultancy and assistance for Brussels technological industry
- Belgian Building Institute (BBRI): Research and assistance in the construction sector
- BRUFOTEC: Assistance and consultancy for the food industry

Research in Europe

ISRIB advises the Brussels authorities on questions related to Belgian, European and international research policy. This contribution is based on its expertise and knowledge of the regional research area.

Moreover, ISRIB takes part in the Belgian decision-making process in research policy:
- participating in the International Cooperation Committee ("CIS")
- following up the European Research programmes (i.e. FP7)
- organizing the Brussels network of the national contact points (NCPs)

Domaine Latour de Freins
Rue Engeland, 555
B - 1180 Brussels (Belgium)

Phone: +32 2 600 50 34
Fax: +32 2 600 50 47

E-mail
cmay@irsib.irisnet.be

Website
www.irsib.irisnet.be

ISRIB Director
Claude May

Contact person
Claire Léautey

E-mail
cleautey@irsib.irisnet.be

PHARMA.BE

Chaussée de la Hulpe, 166
B - 1170 Brussels (Belgium)

Phone: **+32 2 661 91 00**
Fax: **+32 2 661 91 99**

E-mail
info@pharma.be

Website
www.pharma.be

Contact person
Leo Neels

pharma.be is the General Association for the Medicine Industry. Its role is to represent its member companies to their Belgian healthcare partners in all areas related to medicines, (i.e. regulations,information, budgets, reimbursements,etc).

pharma.be, the General Association for the Medicine Industry (AGIM) was founded in 1966. It currently has 123 pharmaceutical company members operating in Belgium. As a full partner to doctors, health care authorities and others, pharma.be's mission is to promote therapeutical innovation in medicines for human use to ensure the best possible levels of health care. The association's main priority is to help patients benefit as early as possible from the "medicines of tomorrow" developed by Research and Development.

pharma.be is proud to support the pharmaceutical industry, a dynamic, innovative and responsible industry.
The association emphasizes the public health contribution made by the industry through new medicine research and development without losing sight of the importance to the economy of research, clinical testing and medicine production.

Bio & Pharma in Brussels

An initiative of

THE BRUSSELS ENTERPRISE AGENCY

Tour & Taxis
Avenue du Port 86c B 211
B - 1000 Brussels
Phone +32 2 422 00 20
Fax +32 2 422 00 43
www.biopharmainbrussels.be

enterprise europe network
Business Support on Your Doorstep

With the support of BRUSSELS-CAPITAL REGION